Analysis of California Senate Bill 600: Fertility Preservation by California Health Benefits Review Program
UC Office of the President
Report to California Legislature
Title
Analysis of California Senate Bill 600: Fertility Preservation
Permalink
https://escholarship.org/uc/item/26507095
Author
California Health Benefits Review Program
Publication Date
2019-04-17
Data Availability
The data associated with this publication are within the manuscript.
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
  
California Health 
Benefits  
Review Program 
Analysis of California Senate Bill 600 
Fertility Preservation 
A Report to the 2019–2020 California State Legislature April 17, 2019 
 
 
Key Findings: 
Analysis of California Senate Bill 600 
Fertility Preservation 
Summary to the 2019–2020 California State Legislature, April 17, 2019 
Current as of April 17, 2019 
 
                                                     
1 Refer to CHBRP’s full report for full citations and references. 
CONTEXT 
Iatrogenic infertility is medically induced infertility caused 
by a medical intervention used to treat a primary disease 
or condition. Iatrogenic infertility is typically caused by 
cancer treatments, such as radiation and chemotherapy 
(gonadotoxic treatments) or surgical removal of 
reproductive organs. Approximately 90% of iatrogenic 
infertility is caused by cancer treatment.1 Including 
services specified by the American Society of Clinical 
Oncology (ASCO) and American Society for Reproductive 
Medicine (ASRM) guidelines, SB 600 would require 
coverage of: fertility preservation consultation; sperm, 
oocyte, and embryo cryopreservation; and services as 
part of or concurrent with cancer treatment for persons 
likely to experience iatrogenic infertility.  
CHBRP assumes that enrollees have coverage for fertility 
preservation consultation and services that are part of or 
concurrent with cancer treatment; therefore, this report 
focuses on the impacts of requiring plans and policies to 
cover sperm, oocyte, and embryo cryopreservation. 
AT A GLANCE 
The version of California Senate Bill (SB) 600 
analyzed by CHBRP would require coverage for 
medically necessary expenses for standard fertility 
preservation services when a medically necessary 
treatment may directly or indirectly cause iatrogenic 
infertility. 
1. CHBRP estimates that, in 2020, of the 24.5 
million Californians enrolled in state-regulated 
health insurance, 16.9 million of them will 
have insurance subject to SB 600.  
2. Benefit coverage. Some fertility preservation 
services are provided as part of cancer 
treatment and CHBRP assumes 100% of 
enrollees have coverage for these standard 
services. However, 0.9% of enrollees currently 
have benefit coverage for sperm, oocyte, and 
embryo cryopreservation, which are classified 
as standard fertility preservation services by 
ACSO and ASRM. Benefit coverage would 
increase to 100% postmandate. SB 600 is 
unlikely to exceed the essential health 
benefits.  
3. Utilization. The number of enrollees utilizing 
sperm, oocyte, and embryo cryopreservation 
services would increase from 1,102 
premandate to 1,753 postmandate.  
4. Expenditures. Total expenditures would 
increase by $6,773,000 (0.0043%).  
a. This is due to premium increases of 
$8,263,000 and increases in enrollee out-
of-pocket expenses of $3,244,000, offset 
by a decrease of enrollee expenses for 
noncovered services of $4,734,000. 
5. Medical effectiveness. The medical 
effectiveness review found there is: 
a. Preponderance of evidence that sperm, 
oocyte, and embryo cryopreservation is 
an effective method of fertility 
preservation. 
 
AT A GLANCE, Cont.  
 
 
6. Public health. SB 600 could potentially 
increase the rate of physician referrals for 
fertility counseling and preservation by 
providing coverage for such services and 
reducing out-of-pocket costs for patients 
potentially experiencing iatrogenic infertility. 
7. Long-term impacts. Use of cryopreservation 
will lead to some increased utilization of 
infertility treatments to achieve pregnancy 
among the affected enrollees. CHBRP 
estimates utilization of cryopreservation 
services in 2020 would result in additional 86 
live births over a 20-year period.  
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BILL SUMMARY  
SB 600 would require coverage for medically necessary 
expenses for standard fertility preservation services when 
a medically necessary treatment may directly or indirectly 
cause iatrogenic infertility. SB 600 also provides 
definitions of iatrogenic infertility, medical treatment that 
may directly or indirectly cause iatrogenic infertility, 
standard fertility preservation services, and medical 
necessity. Figure A notes how many Californians have 
health insurance that would be subject to SB 600. 
Figure A. Health Insurance in CA and SB 600 
 
Source: California Health Benefits Review Program, 2019. 
Notes: *Medicare beneficiaries, enrollees in self-insured products, etc. 
IMPACTS 
Benefit Coverage, Utilization, and Cost  
Standard fertility preservation services that do not involve 
cryopreservation, such as ovarian transposition, are 
covered by insurance as part of standard cancer 
treatment. Hence, in this analysis CHBRP focused on 
examining specifically the coverage of cryopreservation of 
sperm, mature oocytes, and embryos, including all 
procedures to harvest the materials and storage for 1 
year, among enrollees in DMHC-regulated health plans 
and CDI-regulated policies in California. 
Benefit Coverage 
Currently, 0.9% of enrollees with health insurance that 
would be subject to SB 600 have coverage for 
cryopreservation services for sperm, mature oocytes, and 
embryos. Postmandate, the coverage for cryopreservation 
would increase to 100%.  
Utilization 
CHBRP estimates that in the first year postmandate, SB 
600 would result in 792 male and 961 female enrollees 
with cancer using cryopreservation services.  
Of the 792 male users postmandate, 136 enrollees would 
be new users of sperm cryopreservation. The estimated 
639 male cryopreservation users at baseline using 
cryopreservation without coverage would experience 
financial relief postmandate, because coverage would be 
available to them. Of the 961 female users postmandate, 
516 enrollees would be new users (123 new users of 
embryo cryopreservation and 392 new users of mature 
oocyte cryopreservation). A total of 428 female enrollees 
(102 users of embryo cryopreservation and 326 of mature 
oocyte cryopreservation) would use cryopreservation with 
coverage postmandate, whereas they were using the 
services without coverage at baseline. 
Expenditures 
SB 600 would increase net annual expenditures by total 
net annual $6,773,000 or total net annual 0.0043% for 
enrollees with DMHC-regulated plans and CDI-regulated 
policies. This is due to a $8,263,000 increase in total 
health insurance premiums paid by employers and 
enrollees for newly covered benefits, adjusted by a 
$4,734,000 decrease in enrollee expenses for noncovered 
benefits. 
Figure B. Expenditure Impacts of SB 600 
 
Source: California Health Benefits Review Program, 2019.  
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Enrollee Out-of-Pocket Spending 
About 10% of enrollees in the nongrandfathered large 
group and 100% of enrollees in the Covered California 
individual markets with coverage for cryopreservation 
have the same cost-sharing structure as major medical 
services. CHBRP assumed the cost-sharing structure for 
cryopreservation would involve a 50% coinsurance, 
based, for all other enrollees. Cost-sharing impacts (not 
including premiums) among enrollees using 
cryopreservation would range from $184 for CalPERS 
HMO enrollees to $1,051 for enrollees in small group 
plans. 
Medi-Cal 
SB 600 does not apply to Medi-Cal beneficiaries, and 
therefore, there would be no impact.  
CalPERS 
Premium employer expenditures would increase by 
$271,000 (0.0087%) for CalPERS enrollees. Enrollees 
would also see a corresponding increase in employee 
premiums and out-of-pocket expenses, but a decrease in 
enrollee expenses for noncovered benefits.  
Number of Uninsured in California 
SB 600 would not result in premium increases of more 
than 1%, and therefore, there would be no measurable 
impact on the number of uninsured in California.  
Medical Effectiveness 
Recommendations issued by the ASCO in July 2018 
indicate that cryopreservation is considered standard 
practice for fertility preservation in cancer patients. As 
discussed above, cryopreservation is not a widely covered 
form of fertility preservation. Therefore, the Medical 
Effectiveness review examined whether sperm, oocyte, 
and embryo cryopreservation services used for fertility 
perseveration resulted in pregnancy and live births, 
among other outcomes. 
• There is a preponderance of evidence that 
sperm, oocyte, and embryo cryopreservation 
are effective methods of preserving fertility.  
Other standard fertility preservation services, such as 
shielding and ovarian transposition, are all covered by 
insurance as part of standard cancer treatment. Additional 
fertility preservation services — ovarian suppression with 
hormones for female breast cancer patients, 
cryopreservation of ovarian tissue and testicular tissue, 
testicular suppression with hormones during radiation, and 
maturation of oocytes outside of the body — are either 
considered experimental or not broadly recommended. 
Public Health 
SB 600 would likely improve the quality of life by reducing 
regret about fertility outcomes, dissatisfaction, and 
distress for the additional 651 enrollees newly using 
fertility preservation services to prevent iatrogenic 
infertility. SB 600 could potentially increase the rate of 
physician referrals for fertility counseling and preservation 
by providing coverage for such services and reducing out-
of-pocket costs for patients experiencing iatrogenic 
infertility.  
In California, females have twice the rate of cancers with 
treatments causing iatrogenic infertility as males; 
furthermore, females pay 23 times more for uncovered 
fertility preservation services than males. Postmandate, 
SB 600 would decrease the gender disparity by reducing 
the financial burden, thereby bringing costs between 
genders to parity, and reduce the cost consideration from 
a woman’s decision-making process regarding iatrogenic 
infertility risk. However, CHBRP estimates that some 
females would still face greater out-of-pocket expense 
burdens than males, postmandate, due to differences in 
costs of sex-specific preservation methods (e.g., more 
office visits, prescription drug cost, procedure costs) and 
insurance cost-sharing structures. 
Long-Term Impacts 
When the enrollee is ready to use the cryopreserved 
material at some point in the future, they would incur costs 
associated with infertility treatments, such as in vitro 
fertilization. Costs for this treatment incurred by the 
enrollee would be dependent on whether or not infertility 
treatment is covered by insurance and the level of 
coverage. Use of cryopreservation will lead to some 
increased utilization of infertility services to achieve 
pregnancy among the affected enrollees. CHBRP 
estimates utilization of cryopreservation services in 2020 
would result in additional 86 live births over a 20-year 
period. 
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Essential Health Benefits and the 
Affordable Care Act 
SB 600 is unlikely to exceed EHBs. DMHC confirmed to 
CHBRP that under existing law, fertility preservation to 
address potential iatrogenic infertility is a basic health care 
service within the meaning of Health and Safety Code 
section 1345(b) when medically necessary for the 
enrollee.
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ABOUT CHBRP 
The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing 
statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, 
and public health impacts of proposed health insurance benefit-related legislation. The state funds 
CHBRP through an annual assessment on health plans and insurers in California.  
An analytic staff based at the University of California, Berkeley, supports a task force of faculty and 
research staff from multiple University of California campuses to complete each CHBRP analysis. A 
strict conflict-of-interest policy ensures that the analyses are undertaken without bias. A certified, 
independent actuary helps to estimate the financial impact. Content experts with comprehensive 
subject-matter expertise are consulted to provide essential background and input on the analytic 
approach for each report.  
More detailed information on CHBRP’s analysis methodology, authorizing statute, as well as all 
CHBRP reports and other publications are available at www.chbrp.org. 
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Table 1. SB 600 Impacts on Benefit Coverage, Utilization, and Cost, 2020 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with 
health insurance 
subject to state-level 
benefit mandates (a) 24,490,000 24,490,000 0 0% 
 Total enrollees with 
health insurance 
subject to SB 600 16,899,000 16,899,000 0 0% 
 Percentage of 
enrollees with health 
insurance subject to 
SB 600 69% 69% 0 0% 
 Number of enrollees 
with fertility 
preservation coverage 
fully compliant with SB 
600 158,992 16,899,000 16,740,008 10,529% 
 Percentage of 
enrollees with fertility 
preservation coverage 
fully compliant SB 600 0.94% 100% 99% 10,529% 
Utilization and unit cost 
 Number of enrollees of child-bearing age with cancer diagnosis where treatment might result in 
iatrogenic infertility 
    Male 2,553 2,553 0 0% 
    Female 3,799 3,799 0 0% 
    Total 6,352 6,352 0 0% 
 Number of enrollees with cancer using cryopreservation covered by insurance 
    Embryo  2 227 225 11,955% 
    Mature oocyte  16 734 718 4,601% 
    Sperm  17 792 775 4,650% 
 Number of enrollees with cancer using cryopreservation not covered by insurance 
    Embryo  102 0 -102 -100% 
    Mature oocyte  326 0 -326 -100% 
   Sperm  639 0 -639 -100% 
 Average cost per cryopreservation procedure 
    Embryo  $11,254  $11,254  0 0% 
    Mature oocyte  $10,078  $10,078  0 0% 
    Sperm  $468  $468  0 0% 
Expenditures 
Premiums by payer 
 Private employers for 
group insurance 
$86,438,375,000 $86,444,142,000 $5,767,000 0.0067% 
 CalPERS HMO 
employer expenditures 
(c) (b) 
$3,098,551,000 $3,098,822,000 $271,000 0.0087% 
 Medi-Cal Managed 
Care Plan 
expenditures 
$28,492,273,000 $28,492,273,000 $0 0.0000% 
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 Enrollees with 
individually purchased 
insurance 
$12,045,324,000 $12,046,641,000 $1,317,000 0.0109% 
 Enrollees with group 
insurance, CalPERS 
HMOs, Covered 
California, and Medi-
Cal Managed Care (c) 
$14,476,394,000 $14,477,302,000 $908,000 0.0063% 
Enrollee expenses 
 For covered benefits 
(deductibles, 
copayments, etc.) 
$14,750,880,000 $14,754,124,000 $3,244,000 0.0220% 
 Enrollee expenses for 
noncovered benefits 
(d) 
 
$4,734,000 0 -$4,734,000 -100% 
Total expenditures $159,306,531,000 $159,313,304,000 $6,773,000 0.0043% 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in 
employer-sponsored health insurance. This group includes commercial enrollees (including those associated with Covered 
California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.2  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that will be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations. 
 
 
                                                     
2 For more detail, see Estimates of Sources of Health Insurance in California, available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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POLICY CONTEXT 
The California Senate Committee on Health has requested that the California Health Benefits Review 
Program (CHBRP)3 conduct an evidence-based assessment of the medical, financial, and public health 
impacts of SB 600, Fertility Preservation. 
Bill-Specific Analysis of SB 600, Fertility Preservation 
Bill Language 
SB 600 would require individual and group health plans and policies to cover medically necessary 
expenses for standard fertility preservation services when a medically necessary treatment may directly 
or indirectly cause iatrogenic infertility. The full text of SB 600 can be found in Appendix A. 
SB 600 provides the following definitions:  
 “Iatrogenic infertility” means an impairment of fertility caused directly or indirectly by surgery, 
chemotherapy, radiation, or other medical treatment.  
 Medical treatment that “may directly or indirectly cause iatrogenic infertility” means medical 
treatment with a possible side effect of impaired fertility, as established by the American Society 
of Clinical Oncology (ASCO) or the American Society for Reproductive Medicine (ASRM), or 
other reputable professional medical organization.  
 “Standard fertility preservation services” means the procedures consistent with the established 
medical practices and professional guidelines published by ASCO, ASRM, or other reputable 
professional organizations.  
 “Medical necessity” means when a provider states there is a substantial likelihood that treatment 
may directly or indirectly cause iatrogenic infertility to an enrollee. A plan or policy cannot deny 
coverage for services based on medical necessity if so declared by the provider.  
CHBRP has previously analyzed legislation requiring coverage of Fertility Preservation: AB 428 in 2011, 
AB 912 in 2013, and SB 172 in 2017. This analysis builds on these previous reports.4  
Relevant Populations 
If enacted, SB 600 would affect the health insurance of approximately 16.9 million enrollees (43% of all 
Californians). This represents 69% of Californians who will have health insurance regulated by the state 
that may be subject to any state health benefit mandate law — health insurance regulated by the 
California Department of Managed Health Care (DMHC) or the California Department of Insurance (CDI). 
Medi-Cal beneficiaries would not be subject to SB 600 and are therefore excluded from this analysis.5  
                                                     
3 CHBRP’s authorizing statute is available at http://chbrp.org/faqs.php. 
4 CHBRP reports are available at: http://chbrp.com/.  
5 The regulator, DMHC, and the purchaser, the California Department of Health Care Services, have indicated that by 
referencing “group” plans, SB 600 would not require compliance from plans enrolling Medi-Cal beneficiaries into 
Medi-Cal Managed Care. C. Robinson, Department of Health Care Services, citing Sec. 2791 of the federal Public 
Health Service Act, January 2014.  
Analysis of California Senate Bill 600 
Current as of April 17, 2019 www.chbrp.org 2 
Interaction With Existing Requirements 
Health benefit mandates may interact and align with the following state and federal mandates or 
provisions. 
California Policy Landscape 
California law and regulations 
Current California law requires group CDI-regulated policies and most group DMHC-regulated plans to 
offer coverage for infertility treatment, except in vitro fertilization.6,7,8  This statute does not require 
coverage for fertility preservation services. However, AB 767 (Wicks) Infertility, introduced in 2019, would 
alter this benefit. Please see CHBRP’s April 2019 analysis of AB 767 for more information regarding 
infertility services.  
Other existing California state benefit mandates require coverage for various aspects of the screening, 
diagnosis, and treatment of cancer. However, these existing state benefit mandates do not explicitly 
require coverage for fertility preservation services as part of cancer treatment. 
CHBRP reviewed the state’s Independent Medical Review (IMR) determinations and found three 
determinations related to fertility preservation. The decision most relevant to SB 600 involved a 33-year 
old woman who requested embryo cryopreservation following a breast cancer diagnosis.9 The decision 
noted that embryo cryopreservation is the best established method of fertility preservation. The IMR 
decision ruled that this was an appropriate therapy, and the enrollee’s only option to preserve fertility; the 
health plan’s decision was overturned.  
Another decision involved an enrollee request for a fertility specialist consultation and potential egg 
retrieval and use of a surrogate.10 Partially due to the patient’s age, the IMR deemed that the patient’s 
request was medically necessary, and the health plan decision was overturned. The third decision 
involved an enrollee undergoing gender transition (aged 11–20 years) whose parents requested oocyte 
cryopreservation.11 The reviewers noted it was not clear whether the patient had expressed a desire to 
preserve his fertility, and thus, the reviewers deemed that the service was not medically necessary for the 
enrollees’ treatment. The IMR decision upheld the health plan’s decision.   
Similar requirements in other states 
A recent wave of state mandates have expanded what insurers must cover in the area of infertility 
treatment. Since 2017, 16 states have introduced legislation that would mandate coverage of fertility 
preservation — which includes the removal and storage of oocytes and sperm — prior to radiation and 
                                                     
6 H&SC Section 1374.55 and IC Section 10119.6. 
7 California code defines (1) the presence of a demonstrated condition recognized by a licensed physician and 
surgeon as a cause of infertility, or (2) the inability to conceive a pregnancy or to carry a pregnancy to a live birth after 
a year or more of regular sexual relations without contraception. “Treatment for infertility” means procedures 
consistent with established medical practices in the treatment of infertility by licensed physicians and surgeons 
including but not limited to diagnosis, diagnostic tests, medication, surgery, and gamete intrafallopian transfer. “In 
vitro fertilization” means the laboratory medical procedures involving the actual in vitro fertilization process. 
8 While California does not require plans or policies to offer coverage for in vitro fertilization, the state does require 
that plans offer coverage for gamete intrafallopian transfer (GIFT). http://www.asrm.org/insurance.aspx 
9 IMR Reference ID EI11-12274. 
10 IMR Reference ID MN15-20864. 
11 IMR Reference ID EI15-20978. 
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chemotherapy treatment for cancer. Five states — Connecticut, Rhode Island, Maryland, Delaware, and 
Illinois — have enacted this legislation (Reinecke, 2018). New York recently enacted a budget measure 
mandating coverage for in vitro fertilization (IVF) and medically necessary egg freezing. 
• In July 2017, Rhode Island became the first state to pass legislation mandating fertility 
preservation coverage prior to medical treatment that could render a patient infertile, setting a 
new precedent nationwide. 
• Taking effect in January 2018, Connecticut’s House Bill (HB) 5968 requires health insurance 
coverage for fertility preservation for insured persons diagnosed with cancer specifically.12  
• In May 2018, Maryland signed into law legislation that would require coverage for fertility 
preservation for cancer patients who face infertility from their treatments (SB 271/ HB 908) 
• In 2018, Delaware became the fourth state to cover fertility preservation services, with the 
passage of Senate Bill 139. The bill requires insurers to cover fertility preservation services for 
anyone who needs medically necessary health care that could cause iatrogenic infertility. Any 
fertility preservation services that are consistent with ASRM and ASCO guidelines are eligible for 
coverage.  
• In 2018, Illinois became the fifth state to enact fertility preservation coverage with the passage of 
HB 2617. 
• In April 2019, New York enacted a budget measure in the 2020 state budget that mandates 
certain large-group insurance plans cover IVF, and requires all private insurance companies to 
cover medically necessary egg freezing. 
 
Federal Policy Landscape 
On the federal level, in May 2018, the Access to Infertility Treatment and Care Act (H.R. 5965 and S. 
2920), was introduced. Although not enacted, this bill would have required health plans in group and 
individual markets to cover fertility preservation services for patients undergoing medically-necessary 
procedures that may result in infertility, as well as treatments for infertility (Reinecke, 2018). 
Affordable Care Act 
A number of Affordable Care Act (ACA) provisions have the potential to or do interact with state benefit 
mandates. Below is an analysis of how SB 600 may interact with requirements of the ACA as presently 
exists in federal law, including the requirement for certain health insurance to cover essential health 
benefits (EHBs).13 
Any changes at the federal level may impact the analysis or implementation of this bill, were it to pass into 
law. However, CHBRP analyzes bills in the current environment given current law and regulations.  
                                                     
12 Connecticut House Bill 5968. Available at: 
https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=HB05968&which_year=2017. 
13 The ACA requires nongrandfathered small-group and individual market health insurance — including but not limited 
to QHPs sold in Covered California — to cover 10 specified categories of EHBs. Resources on EHBs and other ACA 
impacts are available on the CHBRP website: http://www.chbrp.org/other_publications/index.php. 
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Essential Health Benefits 
State health insurance marketplaces, such as Covered California, are responsible for certifying and 
selling qualified health plans (QHPs) in the small-group and individual markets. QHPs are required to 
meet a minimum standard of benefits as defined by the ACA as essential health benefits (EHBs). In 
California, EHBs are related to the benefit coverage available in the Kaiser Foundation Health Plan Small 
Group Health Maintenance Organization (HMO) 30 plan, the state’s benchmark plan for federal EHBs.14,15 
States may require QHPs to offer benefits that exceed EHBs.16 However, a state that chooses to do so 
must make payments to defray the cost of those additionally mandated benefits, either by paying the 
purchaser directly or by paying the QHP.17,18 State rules related to provider types, cost sharing, or 
reimbursement methods would not meet the definition of state benefit mandates that could exceed 
EHBs.19  
SB 600 is unlikely to exceed EHBs. DMHC confirmed to CHBRP that under existing law, fertility 
preservation to address potential iatrogenic infertility is a basic health care service within the meaning of 
Health and Safety Code section 1345(b) when medically necessary for the enrollee. However, CDI said 
the current EHB benchmark plan does not include standard fertility preservation services, as defined.20 
CHBRP assumes that DMHC, which also regulates the Kaiser Foundation Health Plan Small Group HMO 
30 plan, the state’s benchmark plan for federal EHBs, is correct in their interpretation of whether SB 600 
would exceed EHBs. DMHC provided a letter to Senator Portantino’s office in response to a request for 
clarification regarding coverage of fertility preservation, in which DMHC confirmed medically necessary 
fertility preservation services are covered under the Knox-Keene Act’s requirement that health plans must 
cover all basic health care services.21  
Analytic Approach and Key Assumptions 
Iatrogenic infertility 
Iatrogenic infertility is medically induced infertility caused by a medical intervention used to treat a primary 
disease or condition. Iatrogenic infertility is typically caused by cancer treatments, such as radiation and 
chemotherapy (gonadotoxic treatments) or surgical removal of reproductive organs. Less frequently, 
fertility is compromised by treatments for autoimmune disorders such as systemic lupus erythematosus or 
                                                     
14 The U.S. Department of Health and Human Services (HHS) has allowed each state to define its own EHBs for 
2014 and 2015 by selecting one of a set of specified benchmark plan options. CCIIO, Information on Essential Health 
Benefits Benchmark Plans. Available at: https://www.cms.gov/cciio/resources/data-resources/ehb.html.  
15 H&SC Section 1367.005; IC Section 10112.27. 
16 ACA Section 1311(d)(3). 
17 State benefit mandates enacted on or before December 31, 2011, may be included in a state’s EHBs, according to 
the U.S. Department of Health and Human Services (HHS). Patient Protection and Affordable Care Act: Standards 
Related to Essential Health Benefits, Actuarial Value, and Accreditation. Final Rule. Federal Register, Vol. 78, No. 37. 
February 25, 2013. Available at: www.gpo.gov\fdsys\pkg\FR-2013-02-25\pdf\2013-04084.pdf. 
18 However, as laid out in the Final Rule on EHBs HHS released in February 2013, state benefit mandates enacted 
on or before December 31, 2011, would be included in the state’s EHBs and there would be no requirement that the 
state defray the costs of those state mandated benefits. For state benefit mandates enacted after December 31, 
2011, that are identified as exceeding EHBs, the state would be required to defray the cost. 
19 Essential Health Benefits. Final Rule. A state’s health insurance marketplace would be responsible for determining 
when a state benefit mandate exceeds EHBs, and QHP issuers would be responsible for calculating the cost that 
must be defrayed. 
20 IC Section 10112.27a-Ai 
21 Letter provided to CHBRP by Senator Portantino’s office and bill sponsors, dated 12/21/2018.  
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rheumatoid arthritis or Crohn’s disease (Bermas and Sammaritano, 2015; Lawrenz et al., 2011). 
Autoimmune conditions sometimes require gonadotoxic or surgical treatments (Bermas and 
Sammaritano, 2015); individuals with gender and sex diversity such as individuals who are transgender 
may also undergo gonadotoxic treatments. 
Because approximately 90% of iatrogenic infertility is caused by cancer treatment (Lawrenz et al., 2011), 
for this analysis CHBRP focuses on iatrogenic infertility attributable to cancer treatments. The fertility 
preservation studies identified by the CHBRP literature search were almost exclusively focused on the 
cancer population (see the Medical Effectiveness section). In addition, there are no evidence-based 
recommendations for fertility preservation for patients outside of cancer patients, and thus the research 
on fertility preservation has focused almost exclusively on this group.22 Lastly, This approach was 
confirmed by a clinical content expert with expertise in reproductive medicine. 
Fertility preservation 
The National Cancer Institute defines fertility preservation as a type of procedure used to maintain an 
individual’s ability to have biological children. If a patient is expected to undergo a treatment that could 
increase the risk of iatrogenic infertility, the patient and their provider may pursue fertility preservation 
services prior to the treatment. For example, a cancer patient who is currently not experiencing infertility 
may choose to undergo fertility preservation services before beginning a gonadotoxic treatment that may 
cause iatrogenic infertility. 
Patients at risk for iatrogenic infertility differ from patients being treated for infertility in that they need to 
take steps to preserve their fertility prior to undergoing treatment that may put them at risk of infertility. 
Most cancer patients will not know beforehand if their treatment will lead to infertility. Fertility preservation 
services are also distinct from infertility treatment. Infertility is defined as the inability to conceive after 12 
months of unprotected intercourse.23 Infertility treatments occur while a patient is already experiencing 
infertility. Conversely, fertility preservation services occur before a patient experiences infertility or may be 
at risk for infertility.  
CHBRP’s analysis of SB 600 focuses on fertility preservation services in conjunction with a cancer 
diagnosis and cancer treatment. As specified by ASCO and ASRM, SB 600 would require coverage of: 
fertility preservation consultation; sperm, oocyte, and embryo cryopreservation; and services as part of or 
concurrent with cancer treatment for persons likely to experience iatrogenic infertility.  
CHBRP assumes that enrollees have coverage for fertility preservation consultation and services that are 
part of or concurrent with cancer treatment; therefore, this report focuses on the impacts of requiring 
plans and policies to cover sperm, oocyte, and embryo cryopreservation. Table 2 in the Background 
section describes the services considered part of the standard of care during cancer treatment and the 
Medical Effectiveness section summarizes all fertility preservation services listed by ACSO and ASRM.  
                                                     
22 In 2015, the American Society of Reproductive Medicine published a statement that transgender patients should be 
informed of and offered fertility preservation services before gender confirmation treatment. The statement also 
notes: “There are currently no practice guidelines for physicians providing fertility preservation and reproductive care 
to transgender patients…. However, further research is needed to provide evidence-based and patient-centered 
care….”  
23 https://www.asrm.org/topics/topics-index/infertility/ 
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Coverage for fertility preservation services versus coverage for infertility treatment 
An enrollee may have coverage for infertility treatment, but may not have coverage for fertility 
preservation services, and vice versa. SB 600 would not require coverage of infertility treatment nor 
would it affect current coverage rates for infertility treatment.  
Current California law requires group CDI-regulated policies and most group DMHC-regulated plans to 
offer coverage for infertility treatment.24 “Mandate to offer” means all health care service plans and health 
insurers selling health insurance subject to the mandate are required to offer coverage for the benefit for 
purchase. The health plan or insurer may comply with the mandate either (1) by including the benefit as 
standard in its health insurance products, or (2) by offering coverage for the benefit separately at an 
additional cost (e.g., a rider). “Mandate to cover” means that all health insurance subject to the law must 
cover the benefit. 
 
 
                                                     
24 H&SC Section 1374.55 and IC Section 10119.6. 
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BACKGROUND ON FERTILITY PRESERVATION FOR 
IATROGENIC INFERTILITY 
Fertility preservation services provide patients at risk for iatrogenic infertility with the opportunity to have 
future fertility following gonadotoxic treatments (e.g., radiation, chemotherapy, prolonged endocrine 
therapy, gonadotoxic medications, surgery). In order to preserve reproductive capabilities, fertility 
preservation services are obtained prior to primary disease treatment. Table 2 describes the standard 
(nonexperimental) types of fertility preservation services, and whether they are subject to SB 600. (Note 
that CHBRP assumes harm reduction procedures and conservative gynecologic surgery are covered by 
an enrollee’s medical benefit for cancer treatment.)  
The selection of an appropriate fertility preservation service for patients at risk for iatrogenic infertility 
varies by the age and gender of the patient, the patient’s relationship status, cultural and religious beliefs, 
and the type of cancer treatment the patient is undergoing. For example, a female adolescent may be 
more likely to choose oocyte cryopreservation over embryo cryopreservation, compared to an older 
woman with a partner.  
SB 600 addresses the first stage of fertility care: fertility preservation services. However, at some point, 
cancer survivors may choose to have a child and retrieve cryopreserved sperm, oocytes, or embryos to 
use for artificial insemination or in vitro fertilization; the timeframe for retrieval has been documented to 
range from 1 to 10 years later (Oktay and Oktem, 2010). Note that SB 600 does not require coverage for 
the follow-up assisted reproductive technologies (ART) such as artificial insemination, in vitro fertilization, 
and/or embryo transfer.25  Additionally, after gonadotoxic therapies many patients will not achieve 
pregnancy through infertility treatment if they have not taken fertility preservation measures first. 
 
 
Table 2. Summary of Types of Fertility Preservation and SB 600 Coverage Status 
Preservation 
Service 
Definition of  
Service 
FP Service  
Timing (a) 
Other 
Considerations 
Covered by 
SB 600?  
Cryopreservation 
Embryo 
cryopreservation  
Ovarian stimulation via 
outpatient hormone 
prescriptions; harvesting 
oocytes, IVF, and freezing of 
embryos 
Occurs before or during 
cancer treatment 
Outpatient process 
takes 10–15 days  
Need partner or donor 
sperm 
Yes 
Oocyte 
cryopreservation 
Ovarian stimulation; harvesting 
and freezing of unfertilized 
oocytes 
Occurs before or during 
cancer treatment 
Outpatient process 
takes 10–15 days 
  Yes 
Sperm 
cryopreservation  
Collection and freezing of 
sperm  
Occurs before cancer 
treatment  
Outpatient process 
takes 1–2 days 
 Yes 
                                                     
25 For more information about the aforementioned infertility treatments see CHBRP’s 2019 analysis of AB 767 at 
chbrp.org. 
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Preservation 
Service 
Definition of  
Service 
FP Service  
Timing (a) 
Other 
Considerations 
Covered by 
SB 600?  
Harm reduction (b) 
Ovarian shielding 
during radiation 
therapy (radiation 
shielding)  
Use of shielding to reduce 
scatter radiation to the ovaries 
Occurs in conjunction 
with radiation 
treatments 
Does not protect 
against effects of 
chemotherapy 
Already 
covered 
Testicular shielding 
during radiation 
therapy (radiation 
shielding) 
Using shielding to reduce the 
dose of radiation delivered to 
the testicles during cancer 
treatment 
Occurs in conjunction 
with radiation 
treatments 
Does not protect 
against effects of 
chemotherapy 
Already 
covered 
Ovarian 
transposition 
(oophoropexy) 
Surgical repositioning of 
ovaries out of radiation field 
Occurs before 
treatment. Outpatient 
procedure (1 week of 
recovery time) 
 
Already 
covered 
Conservative gynecologic surgery 
Radical 
trachelectomy 
Surgical removal of the cervix 
with preservation of the uterus 
Inpatient surgical 
procedure 
Limited to early stage 
cervical cancer 
Already 
covered 
Conservative 
ovarian cancer 
surgery (c) 
The conservative treatment 
preserves the uterus and one 
ovary, in cases where cancer 
was confined to just one ovary 
During cancer surgery  
Already 
covered 
Hormone suppression 
Gonadotropin-
releasing hormone 
agonist therapy 
The use of a hormone that 
causes the ovaries to 
temporarily shut down during 
chemotherapy, thus potentially 
reducing damage to the follicles 
where eggs develop 
Occurs in conjunction 
with chemotherapy  
Only recommended 
for women undergoing 
treatment for breast 
cancer 
Potentially 
Source: California Health Benefits Review Program, 2019. (Adapted from a table by Save My Fertility, an initiative of 
the Oncofertility Consortium at Northwestern University and the Endocrine Society with input from content expert, Dr. 
H. Irene Su, Associate Professor of Reproductive Medicine at the University of California, San Diego). 
Notes: (a) “During” treatment is defined as preservation services occurring after surgery and before chemotherapy, radiation, or 
other gonadotoxic medication administration. 
(b) These treatments are already covered and would not be affected by the coverage proposed in SB 600. 
(c) The standard treatment for ovarian cancer is the removal of the uterus (hysterectomy) and removal of both ovaries.  
Key: FP = fertility preservation. 
Incidence of Diseases With Treatments Likely to Result in Iatrogenic 
Infertility  
As discussed in the Policy Context section, CHBRP relies on rates of cancer among men and women of 
reproductive age as a proxy of the number of fertility preservation users because cancer treatments are 
estimated to be the largest contributor to iatrogenic infertility.  
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The definition of reproductive age for purposes of iatrogenic infertility due to cancer treatment is typically 
under 45 years old, including children aged 0 to 15 years whose cancer treatment could impact their 
future fertility (Reinecke et al., 2012). According to data from the California Cancer Registry, more than 
8,000 Californians of reproductive age (2,950 males and 5,701 females aged 10 to 44 years), regardless 
of insurance status, are diagnosed annually with a cancer whose treatments are likely to result in 
iatrogenic infertility (see Table 3) (CDC, 2019). The increased risk of iatrogenic infertility for women is due 
to the high incidence of breast cancer. 
Table 3. Incidence of Cancer Using Treatments Likely to Result in Iatrogenic Infertility for Californians 
Aged 10–44 Years Regardless of Insurance Status, 2015 
Cancer Type Female Male 
 Count Rate per 
100,000 
Count Rate per  
100,000 
Breast 2,887 31.2 — — 
Cervix uteri 528 5.7 — — 
Corpus uteri 429 4.6 — — 
Ovarian 357 3.9 — — 
Male genital — — 1,035 10.7 
Colon and rectum 471 5.1 244 5.3 
Hodgkin lymphoma 197 2.1 454 2.5 
Non-Hodgkin lymphoma 278 3.0 408 4.7 
Leukemia  318 3.4 513 4.2 
Brain/CNS 236 2.5 296 3.1 
Total 5,701 61.5 2,950 30.6 
Source: California Health Benefits Review Program, 2019. Based on CDC, 2019.  
Note: Cancer incidence estimates are based on data from the CDC WONDER database, which does not indicate treatment type. 
Not all cancer treatments affect fertility (e.g., surgery and radiation for breast cancer), so this table may present an overestimation of 
the number of individuals at risk for iatrogenic infertility from cancer treatment. 
Key: CNS = central nervous system. 
Incidence of Iatrogenic Infertility 
The extent to which patients will become infertile after undergoing cancer treatment varies by sex, age, 
type of cancer, and type and duration of treatment (Coccia et al., 2014; Lambertini et al., 2016). For 
example, rates of ovarian failure due to chemotherapy averages 38% regardless of age; however, dose-
related risk for premature menopause due to lymphoma treatment ranges from 15% (low-dose 
procarbazine) to 64% (cumulative high-dose procarbazine) (Coccia et al., 2014). Men also experience 
varying rates of iatrogenic infertility depending on treatment and dose. For example, more than 90% of 
men receiving procarbazine therapy experience azoospermia (sperm absent from semen), whereas other 
chemotherapies permit fertility to return soon after treatment concludes (Coccia et al., 2014). The 
Livestrong Foundation developed a fertility risk tool that shows risk estimates for different types of 
cancers and treatments for males and females ranging from low/no risk for thyroid cancer to 80% 
amenorrhea (cessation of menses) for ovarian cancer (Livestrong, 2017). Because it is unknown who will 
experience permanent iatrogenic infertility, it is recommended that anyone undergoing gonadotoxic 
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treatments be offered fertility preservation services (Loren et al., 2013). Note that some cases of 
iatrogenic infertility can be temporary, and not all patients receiving gonadotoxic treatments become 
permanently infertile. 
Using probabilities of developing cancer by age26 and gender for the top 10 cancers with treatments most 
likely to lead to iatrogenic infertility (Appendix C), and adjusting for the population subject to SB 600, 
CHBRP estimated that 6,352 cancer patients enrolled in health plans subject to SB 600 (2,553 males and 
3,799 females, see Table 1) would be at risk for infertility due to cancer treatments each year.  
Fertility Preservation: Physician Referral and Counseling 
The fertility preservation guidelines issued by the American Society of Clinical Oncology (ASCO) indicate 
that all patients of childbearing age and prepubescent children should be counseled about their fertility 
preservation options prior to starting treatment that could impair their future fertility (Oktay et al., 2018a). 
One survey reported that although 95% of oncologists discussed fertility risk, 61% rarely or never referred 
patients for fertility preservation (Forman et al., 2010). A 2011 survey showed that less than 50% of 
pediatric oncologists referred patients for fertility preservation overall, and 12% referred female patients 
prior to treatment (Kohler et al., 2011).  
Disparities27 and Social Determinants of Health28 in Iatrogenic Infertility   
Per statute, CHBRP includes discussion of disparities and social determinants of health (SDoH) as it 
relates to fertility preservation for iatrogenic infertility. Disparities are differences between groups that are 
modifiable. CHBRP found literature identifying disparities by specify race/ethnicity, sex, age, and gender 
identity/sexual orientation. 
Race/Ethnicity 
Although the incidence of various cancers is known to disproportionately affect certain minority groups, 
CHBRP found no evidence that evaluated the extent to which iatrogenic infertility varied by race/ethnicity. 
There is a paucity of literature comparing fertility preservation referral and counseling among cancer 
patients of reproductive age by race or ethnicity. Of the three studies CHBRP found, all had small sample 
sizes and statistically insignificant findings showing that whites were more likely to have fertility 
preservation discussions and referrals than minorities (Goodman et al., 2012; Quinn et al., 2015; 
Shnorhavorian et al., 2015). 
                                                     
26 Based on content expert input, this analysis is restricted to those of reproductive age, which is defined as ages 12 
to 44 years for females and ages 12 to 49 years for males.  
27 Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: 
Health disparity is defined as the differences, whether unjust or not, in health status or outcomes within a population. 
Wyatt et al., 2016. 
28 CHBRP defines social determinants of health as conditions in which people are born, grow, live, work, learn, and 
age. These social determinants of health (economic factors, social factors, education, physical environment) are 
shaped by the distribution of money, power, and resources and impacted by policy (adapted from Healthy People 
2020, 2015; CDC, 2014). See CHBRP’s SDoH white paper for further information: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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Sex 
Some studies reported inequity in physician referrals for fertility preservation by sex, with males more 
likely to be referred than females. One reason for differential referral rates is physician perception that 
male fertility preservation is less invasive and more affordable than female fertility preservation methods. 
(Bann et al., 2015; Kohler et al., 2011; Quinn et al., 2015; Shnorhavorian et al., 2015). Costs are lower for 
male fertility preservation methods compared to methods used for females. For males, sperm 
cryopreservation is the standard method of preserving fertility, costing approximately $1,150 in California 
for the initial retrieval of sperm, freezing, and short-term storage of up to 1 year. For females, oocyte and 
embryo cryopreservation are the standard methods of preserving fertility, and they cost, on average, 
$13,350 and $14,150, respectively, in California for the initial retrieval of the oocyte, sperm retrieval and 
fertilization (if applicable), freezing, and short-term storage of up to 1 year.  
Age 
Aside from fertility-conserving surgeries or shielding from radiation, prepubescent cancer patients have 
no available standard of care fertility preservation options because they have not yet produced mature 
oocytes or sperm; there are procedures that harvest ovarian or testicular tissue, but these are considered 
experimental. Although long-term survival following pediatric cancer has increased to more than 80% 
(Salih et al., 2015), permanent infertility remains an adverse late effect of cancer treatment until 
prepubescent fertility preservation technology improves. Following puberty, individuals are able to 
undergo standard of care procedures, including sperm, oocyte, or embryo cryopreservation; and children 
as well as adults may undergo fertility-conserving surgeries and procedures. Goodman et al. (2012) found 
that female adults younger than 35 years received fertility preservation counseling three times as often at 
those over 35 years (odds ratio [OR]29 = 3.3, 95% confidence interval [CI] = 1.4–7.7).  
Gender Identity  
People who identify as transgender and choose gender confirmation surgery or hormonal therapy could 
become infertile; thus, they would be eligible for coverage under SB 600. Pooled estimates from the 
California Health Interview Survey (years 2015 to 2017) indicate that there are approximately 30,000 
transgender persons aged 18 to 24 years and 71,000 transgender persons aged 25 to 64 years living in 
California (0.8% and 0.3% of the California adult population, respectively) (CHIS, 2019; UCLA Center for 
Health Policy Research, 2019). 
Both the American Society of Reproductive Medicine and the Endocrine Society published separate 
statements that patients should be informed about and offered fertility preservation services before 
gender confirmation treatment ASRM, 2015b; Hembree et al., 2009). CHBRP found two small U.S. 
studies assessing transgender persons’ interest in having children. Among a mixed population of 
transgender patients presenting to a large academic medical center in Missouri, about 10% of all 
transgender persons expressed a desire for biological children (Schelble et al., 2017). Similarly, about 
one fourth (25.8%) of transgender adolescents aged 14–17 years expressed an interest in biological 
parenthood when responding to a 2016 online survey, and 60.9% were interested in learning more about 
their fertility options in the future (Chen et al., 2018). The proportion of transgender persons in California 
or the United States undergoing gender confirmation treatment and using fertility preservation is 
unknown; however, three studies of transgender youth and adolescents indicate that utilization of fertility 
preservation services at the time of transition is low, ranging from 3% to 5% of transgender persons who 
attended fertility counseling (Chen et al., 2017; Nahata et al., 2017a; Schelble et al., 2017). 
                                                     
29 The odds ratio is the ratio of the chance of an event occurring in one group compared to the chance of it occurring 
in another group. 
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Societal Impact of Iatrogenic Infertility in California 
The presence of iatrogenic infertility in California/the United States creates a societal impact. In dollar 
terms, the societal impact can be indirect (lost wages, etc.) as well as direct (medical care, etc.). CHBRP 
is unable to find data that describe the larger societal impact of iatrogenic infertility specifically. The 
Benefit Coverage, Utilization, and Cost Impacts estimates cost impacts on payers, including enrollees. 
Such figures represent a subset of the total societal impact related to iatrogenic infertility. 
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MEDICAL EFFECTIVENESS 
As discussed in the Policy Context section, SB 600 would mandate coverage for standard fertility 
preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic 
infertility. The Medical Effectiveness review summarizes findings from the literature on the effectiveness 
of specific fertility preservation services (as described in the Background on Fertility Preservation section).  
This Medical Effectiveness review focuses on three services that would be newly covered under SB 600: 
sperm cryopreservation, oocyte cryopreservation, and embryo cryopreservation. Recommendations 
issued by the American Society of Clinical Oncology (ASCO) in July 2018 indicate that cryopreservation is 
considered standard practice for fertility preservation in cancer patients  (Oktay et al., 2018b). Other 
standard fertility preservation services, such as shielding and ovarian transposition, are all covered by 
insurance as part of standard cancer treatment. Other fertility preservation services — ovarian 
suppression with hormones for female breast cancer patients, cryopreservation of ovarian tissue and 
testicular tissue, testicular suppression with hormones during radiation, and maturation of oocytes outside 
of the body — are not broadly recommended and are described, but no conclusion as to their overall 
effectiveness is presented because they would not be covered by the bill. As described in more detail 
below, the focus of this review is fertility preservation in cancer patients. 
Research Approach and Methods 
Studies of the effects of fertility preservation services for patients at risk for iatrogenic infertility were 
identified through searches of PubMed, the Cochrane Library, and Web of Science. Websites maintained 
by the following organizations that produce and/or index meta-analyses and systematic reviews were also 
searched: the Agency for Healthcare Research and Quality (AHRQ), the International Network of 
Agencies for Health Technology Assessment (INAHTA), the National Health Service (NHS) Centre for 
Reviews and Dissemination, the National Institute for Health and Clinical Excellence (NICE), and the 
Scottish Intercollegiate Guideline Network.  
The search was limited to studies published since 2017 to the present because CHBRP had previously 
conducted thorough literature searches on these topics in 2011, 2013, and 2017 for Assembly Bill (AB) 
428, SB 912, and SB 172, respectively. The search was limited to abstracts of studies published in 
English. Of the 360 articles found in the literature review, 31 were reviewed for potential inclusion in this 
report on SB 600, and a total of 4 studies were included in the medical effectiveness review for this 
report, in addition to those identified as part of previous CHBRP reviews. The other articles were 
eliminated because they did not focus on patients undergoing fertility preservation due to cancer 
treatment or reported findings from case reports or case series, which are considered to be low quality in 
CHBRP’s hierarchy of evidence due to their high risk of bias (California Health Benefits Review Program, 
2019). The other articles were eliminated because they were not limited to patients undergoing fertility 
preservation due to cancer treatment or were case reports or case series, which are considered to be low 
quality in CHBRP’s hierarchy of evidence due to their high risk of bias (California Health Benefits Review 
Program, 2019). A more thorough description of the methods used to conduct the medical effectiveness 
review and the process used to grade the evidence for each outcome measure is presented in Appendix 
B. 
The conclusions below are based on the best available evidence from peer-reviewed and grey literature. 
Unpublished studies are not reviewed because the results of such studies, if they exist, cannot be 
obtained within the 60-day timeframe for CHBRP reports. 
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Key Questions 
1. What is the medical effectiveness of sperm, oocyte, and embryo cryopreservation in preserving 
fertility following cancer treatment?  
2. What are the harms of sperm, oocyte and embryo cryopreservation?  
Methodological Considerations 
Iatrogenic infertility is most commonly caused by cancer treatments such as radiation and chemotherapy 
(gonadotoxic treatments) or surgical removal of reproductive organs. Less frequently, fertility is 
compromised by treatments for autoimmune disorders such as systemic lupus erythematosus, 
rheumatoid arthritis, or Crohn’s disease, or for individuals with gender and sex diversity such as 
individuals who are transgender or those with differences of sex development. The decision was made to 
focus the medical effectiveness review on fertility preservation in cancer patients for three reasons. First, 
the most prevalent types of cancer that impact women of reproductive age have treatments with a high 
likelihood of resulting in iatrogenic infertility. It is estimated that approximately 90% of iatrogenic infertility 
is caused by cancer treatment (Lawrenz et al., 2011). Second, although it is possible for treatment for 
autoimmune disorders to impact fertility, gonadotoxic treatments are not the first-line treatments for these 
conditions and are less frequently found among people of reproductive age (Bermas and Sammaritano, 
2015; Molodecky et al., 2012; Pons-Estel et al., 2010). Third, although treatments for transgender 
patients and individuals with differences in sex development have a high likelihood of resulting in 
iatrogenic infertility, there are no current guidelines for providing fertility preservation in this population; 
therefore, there is limited literature addressing this topic (ASRM, 2015a). This review summarizes findings 
from the literature on fertility preservation services used in conjunction with cancer treatment but also 
includes a discussion of relevant issues for other populations of patients.  
Outcomes Assessed 
The medical effectiveness of fertility preservation services was assessed using the following outcomes:  
1. Clinical pregnancy rate: the percentage of attempts that lead to a pregnancy as confirmed by 
ultrasound early in pregnancy, usually around 7 weeks. 
2. Pregnancy rate: the percentage of attempts that lead to any pregnancy. 
3. Cumulative pregnancy rate: pregnancy rate across multiple attempts. 
4. Birth rate: the percentage of attempts that result in any birth (live births and stillbirths). 
5. Live birth rate: the percentage of attempts that result in a live birth (excludes stillbirths). 
6. Cumulative birth rate: birth rate across multiple attempts.  
Intermediate outcomes were also assessed such as post-thaw survival rate of embryos, oocytes or 
sperm; fertilization rate (how many oocytes become fertilized by sperm); and implantation rate (the 
percentage of embryos that become successfully implanted). Adverse outcomes associated with fertility 
preservation services as measured in the literature were cancer-recurrence rates, preterm delivery rates, 
miscarriage rates, and rates of chromosomal abnormalities.  
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Study Findings30 
Embryo, oocyte, and sperm cryopreservation are methods of fertility preservation endorsed by the 
American Society for Clinical Oncologists (ASCO). CHBRP found evidence that embryo cryopreservation 
is an effective method of fertility preservation. Meta-analyses have found that the clinical pregnancy rate 
is higher among frozen embryos compared to fresh transfers, and data shows that the live birth rate is 
inversely related to patient age. Similarly, CHBRP found evidence that oocyte cryopreservation is an 
effective method of fertility preservation. Women returning to use cryopreserved oocytes saw successful 
implantation of the embryos and resulting live pregnancies. Evidence also shows that men returning to 
use cryopreserved sperm are able to achieve parenthood. 
Effectiveness of Embryo Cryopreservation for Female Cancer Patients 
There are nearly 14,000 births in the United States every year from embryo cryopreservation (SART, 
2016). Embryo cryopreservation involves harvesting the patient’s eggs, using in vitro fertilization (IVF) to 
fertilize the eggs, and freezing any resulting embryos for later implantation. This fertility preservation 
service is available to females who have gone through puberty. The post-thaw survival rate of embryos 
ranges between 35% to 90%, whereas implantation rates are between 8% and 42% (Dunn and Fox, 
2009; Loren et al., 2013; Seli and Tangir, 2005; Wallberg et al., 2009). According to 2016 data from the 
Society of Assisted Reproductive Technology (SART), clinical pregnancies (those resulting in a 
pregnancy confirmed by ultrasound) from frozen embryos ranged from 35% to 55%, and birth rates 
ranged from 23% to 37%, depending on patient age (with higher rates among women younger than 35 
years) (SART, 2016). Two meta-analyses have found that the clinical pregnancy rate is higher among 
frozen embryo transfers compared to fresh embryo transfers (Roque et al., 2013; Zhang et al., 2018). 
Birth rates per embryo transfer using cryopreserved embryos have risen from approximately 28% in 2004 
to 35% in 2011 (Dunn and Fox, 2009; SART, 2016). The live birth rate from embryo cryopreservation 
depends on the age of the patient and the number of embryos available (Lee et al., 2006). SART data 
from 2015 indicated that the percentages of thawed embryo transfers resulting in live births were 
inversely related to age: 44.4% in women less than 35 years of age, 40.1% in the 35 to 37 age group, 
35.0% in the 38 to 40 age group, 30.1% in the 41 to 42 age group, and 25.4% in the >42 age group 
(SART, 2015). However, these studies all have small sample sizes and were not limited to patients 
cryopreserving embryos for fertility preservation. 
CHBRP identified one cohort study published since 2016 assessing the effectiveness of embryo 
cryopreservation among female cancer patients. This cohort was composed of 82 women participating in 
a U.S.-based randomized controlled trial; 34 of these women underwent either oocyte (n = 16) and/or 
embryo cryopreservation (n = 20), and 48 women did not (control group). The age range of the entire 
cohort was 24 to 42 years. After 6 years, 30% (n = 6/20) of women returned to use their preserved 
embryos, resulting in two live births (one patient with a twin pregnancy). The study did not report 
reproductive outcomes among the control group (Chien et al., 2017). 
                                                     
30 The following figures in this section summarize CHBRP’s findings regarding the strength of the evidence for the 
effects fertility preservation services addressed by SB 600. For test, treatments, and services for which CHBRP 
concludes that there is clear and convincing, preponderance, limited, or inconclusive evidence, the placement of the 
highlighted box indicates the strength of the evidence. If CHBRP concludes that evidence is insufficient, a figure that 
states “Insufficient Evidence” will be presented. 
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The previous medical effectiveness review for SB 172 identified two cohort studies (Knopman et al., 
2009; Robertson et al., 2011), two case-control studies (Cardozo et al., 2015; Domingo et al., 2012), and 
two case series (Dolmans et al., 2015; Oktay et al., 2015) reporting on patients cryopreserving embryos 
for fertility preservation. Three of four studies comparing infertility procedures between women 
undergoing gonadotoxic treatments and women seeking IVF for male-factor infertility found no difference 
in outcomes (Cardozo et al., 2015; Domingo et al., 2012; Knopman et al., 2009; Robertson et al., 2011). 
Studies published since 2015 among cancer patients found a 37% to 66% pregnancy rate and a 30% to 
45% live birth rate per embryo transfer (Cardozo et al., 2015; Dolmans et al., 2015; Oktay et al., 2015). 
Summary of findings regarding effectiveness of embryo cryopreservation: There is a 
preponderance of evidence that embryo cryopreservation is an effective method of fertility preservation.  
Figure 1. Effectiveness of Embryo Cryopreservation  
 
Effectiveness of Oocyte (Egg) Cryopreservation for Female Cancer Patients 
For postpubertal women who do not have a partner, who do not wish to use a sperm donor, or have 
objections to freezing embryos, the standard option for preserving fertility is oocyte cryopreservation. Due 
to an advance in technology, the viability of oocytes after thawing has greatly improved, leading the 
American Society for Reproductive Medicine (ASRM) to issue new recommendations in January of 2013 
that oocyte cryopreservation should be offered to patients facing chemotherapy or other gonadotoxic 
therapies (ASRM, 2013). Recommendations issued by ASCO in July 2018 indicate that oocyte 
cryopreservation is considered a standard practice (Oktay et al., 2018b). 
CHBRP identified three cohort studies published since 2016 assessing the effectiveness of oocyte 
cryopreservation among female cancer patients (Chien et al., 2017; Cobo et al., 2018; Diaz-Garcia et al., 
2018). Chien and colleagues reported on a cohort comprised of 82 women participating in a U.S.-based 
randomized controlled trial; 34 of these women underwent either oocyte (n = 16) and/or embryo 
cryopreservation (n = 20), and 48 women did not (control group). The age range of the entire cohort was 
24 to 42 years. After 6 years, none of the women who preserved oocytes had returned to use them 
(Chien et al., 2017). Cobo and colleagues reported on a cohort of women undergoing oocyte 
cryopreservation either due to cancer treatment (n = 1,073) or age-related fertility decline (n = 5,289) in 
Spain. Of those undergoing cryopreservation due to cancer treatment, 7.4% (79 women) returned to use 
their preserved oocytes after a mean storage time of 4.1 years. Eighty-two percent of oocytes were 
successfully thawed with an implantation rate of 32.5%, and there were 18 live births among these 
women (birth rate, 22.8% among women returning to use their preserved oocytes) (Cobo et al., 2018). 
Diaz-Garcia and colleagues also reported on a cohort of Spanish women undergoing fertility preservation 
due to cancer treatment; 1,024 women underwent oocyte cryopreservation, and 800 underwent ovarian 
tissue cryopreservation. Of those undergoing oocyte cryopreservation, 4.8% (n = 49) returned to use their 
preserved oocytes after a mean storage time of 3.9 years. Seventy-seven percent of oocytes were 
successfully thawed, and there were 16 patients with 17 live births (birth rate, 34.7%) (Diaz-Garcia et al., 
2018).   
The medical effectiveness review for SB 172 also included two studies reporting relevant outcomes after 
oocyte cryopreservation in female cancer patients (Druckenmiller et al., 2016; Martinez et al., 2014). 
Druckenmiller et al. (2016) reported on 176 patients who cryopreserved their oocytes, of which 10 
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returned to retrieve their eggs for 11 cycles of thawing. Among these, there was an 86% oocyte survival 
rate with 9 of 11 cycles leading to an embryo suitable for transfer with a 44% live birth rate per embryo 
transfer. Martinez et al. (2014) reported on 357 patients who cryopreserved oocytes, with 11 returning for 
egg retrieval. Among this group, there was an oocyte survival rate of 92.3%, a fertilization rate of 76.6%, 
and a birth rate of 36.4% (4 births).  
The previous medical effectiveness review summarized four completed randomized controlled trials 
comparing IVF outcomes using cryopreserved oocytes with outcomes using fresh oocytes (Cobo et al., 
2008; Cobo et al., 2010; Parmegiani et al., 2011; Rienzi et al., 2010). Across the four studies identified, 
the oocyte post-thaw survival rate ranged from 90% to 97%, the fertilization rate ranged from 71% to 
79%, the implantation rate ranged from 17% to 41%, the clinical pregnancy rate per embryo transfer 
ranged from 36% to 61%, and the clinical pregnancy rate per thawed oocyte ranged from 4.5% to 12%. 
These rates compared favorably with fresh oocytes (ASRM, 2013; Kato, 2016). A meta-analysis of three 
of the four above articles reported no significant difference in fertilization rates of thawed oocytes (using 
the vitrification freezing method) versus fresh oocytes (OR = 1.02, 95% CI = 0.91–1.13) (Cobo and Diaz, 
2011). Later research also found no differences between fresh and vitrified-warmed oocytes (Forman et 
al., 2012; Parmegiani et al., 2011). One cohort study reported that 1,027 babies were born from 
cryopreserved oocytes in 2014 with no observed increase in congenital abnormalities (Cobo et al., 2014). 
However, these studies were not limited to patients cryopreserving embryos for fertility preservation. 
Summary of findings regarding effectiveness of oocyte cryopreservation: There is a preponderance 
of evidence that oocyte cryopreservation is an effective method of fertility preservation measured by three 
different outcomes: successful thawing of oocytes; successful implantation of embryos; and resulting live 
births. 
Figure 2. Effectiveness of Oocyte Cryopreservation    
 
Effectiveness of Sperm Cryopreservation for Male Cancer Patients 
Sperm cryopreservation is the most established technique for maintaining fertility in men. In this 
technique, sperm is collected prior to the initiation of cancer treatment and then frozen. Males start 
producing sperm after puberty, around 13 to 14 years of age; therefore, this treatment is not appropriate 
for prepubescent males (Levine et al., 2010). Research has indicated that long-term cryopreservation of 
sperm is possible, with reported pregnancies using sperm stored between 10 and 28 years (Levine et al., 
2010).  
CHBRP did not identify any studies published since 2016 reporting on the effectiveness of sperm 
cryopreservation. One new case series was identified, which reported on 898 men who underwent sperm 
cryopreservation between 1983 and 2013 at a single institution in the Netherlands. This report found that 
96 men (10.7%) returned to use their sperm, and 60 men (62.5%) achieved parenthood (22% via 
intrauterine insemination, 32% via in vitro fertilization, and 46% via intracytoplasmic sperm injection) 
(Muller et al., 2016). However, it should be noted that case reports and case series are considered to be 
low-quality in CHBRP’s hierarchy of evidence due to their high risk of bias (California Health Benefits 
Review Program, 2019).  
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The previous review for SB 172 identified one systematic review including 30 studies with a combined 
total of 11,798 patients undergoing sperm cryopreservation. They found that 8% of those who 
cryopreserved their sperm prior to cancer treatment returned to use this sperm, with 49% achieving 
parenthood (Ferrari et al., 2016). The previous review included two case series which found that sperm 
cryopreservation is effective in providing male cancer patients a chance at parenthood (Hourvitz et al., 
2008; van Casteren et al., 2008). 
Summary of findings regarding effectiveness of sperm cryopreservation: There is a preponderance 
of evidence that sperm cryopreservation is an effective method of fertility preservation as measured by 
pregnancy rates and live births.  
Figure 3. Effectiveness of Sperm Cryopreservation  
 
Harms of Fertility Preservation Treatments 
Ovarian hyperstimulation syndrome (OHSS) is a harm specific to oocyte and embryo harvesting for 
cryopreservation. OHSS occurs when the ovaries are hyperstimulated and enlarged to allow oocytes to 
be harvested for cryopreservation, before or after fertilization (for embryo cryopreservation). Clinical 
features of OHSS range be mild (e.g., abdominal distention, diarrhea), moderate (same symptoms as 
mild, along with abdominal fluid buildup visible on ultrasound), severe (e.g., severe abdominal pain, rapid 
weight gain, syncope), or critical (e.g., acute renal failure, sepsis, thromboembolism). An older systematic 
review (including literature published between 1990 and 2002) found that the incidence of moderate 
OHSS ranges from 3% to 6% and severe/critical OHSS ranges from 0.1% to 2%; the incidence of mild 
OHSS is higher, ranging from 20% to 33% of IVF cycles (Delvigne and Rozenberg, 2002). Other harms of 
oocyte and embryo cryopreservation include procedure-related complications, such a bleeding and 
possible infection.  
Fertility Preservation Services Already Covered by Standard Cancer Treatment 
Ovarian and testicular shielding 
Ovarian and testicular shielding during radiation therapy, as well as certain surgeries — ovarian 
transposition (oophoropexy) and conservative gynecologic surgeries — are services covered as part of 
standard cancer treatment. For women undergoing radiation of the pelvis, ovarian transposition 
(oophoropexy) is used to minimize the damage to the ovaries caused by pelvic radiation (Levine et al., 
2010). This surgery involves repositioning the ovaries higher up in the abdomen and away from the 
radiation field. Rates of successful preservation of ovarian function after oophoropexy vary greatly, with a 
reported range of 16% to 92% (Georgescu et al., 2008; Seli and Tangir, 2005; Thibaud et al., 1992). A 
2014 systematic review and meta-analysis of 24 articles representing 892 patients undergoing ovarian 
transposition found that ovarian function was preserved in 90% of the cases. This review also found that 
there was no evidence of metastases to the transposed ovary (Gubbala et al., 2014).  
In order to protect the ovaries or testes during cancer treatment with radiation, a special external shield 
can be placed over the organs to minimize the damage caused by radiation. Ovarian shielding is 
generally used for cervical or vaginal cancer patients undergoing radiation therapy to treat their cancer. 
Expertise in ovarian shielding is needed to ensure that it is done properly (Levine et al., 2010). In addition, 
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questions remain regarding the correct positioning of the shield, given that not all ovaries are in the exact 
same location (Fawcett et al., 2012). Research from case series has shown that testicular shielding 
treatment is effective in reducing the damage to the testicles, but that it is only possible with selected 
radiation fields and anatomy (Ishiguro et al., 2007; Lee et al., 2006). In addition, expertise is required to 
make sure that the shielding does not increase the amount of radiation delivered to the reproductive 
organs (Lee et al., 2006). 
Ovarian transposition 
The 2018 ASCO recommendations indicate that conservative gynecologic surgery should be considered 
for certain kinds of gynecologic cancers if fertility preservation is desired and conservative surgery is 
appropriate given the stage of cancer (Oktay et al., 2018b). The two surgeries specified in the 
recommendations are conservative surgery for cervical cancer (trachelectomy) and conservative surgery 
for ovarian cancer. A trachelectomy is a surgical procedure to remove the cervix while preserving the 
uterus. This procedure is used in place of a hysterectomy (removal of the uterus) as part of cancer 
treatment for patients wanting to preserve their fertility. This procedure is recommended for early-stage 
cervical cancer where the cancer has not spread beyond the cervix. It is estimated that half of women of 
reproductive age diagnosed with cervical cancer are eligible for the procedure (Lee et al., 2006). The 
2018 ASCO recommendations note that this procedure should be restricted to certain stage 1 cervical 
cancers (Oktay et al., 2018b). The standard treatment for ovarian cancer, including borderline ovarian 
tumor, is removal of the uterus (hysterectomy) and removal of both ovaries. Conservative surgeries 
preserve one ovary with or without the uterus. This is only possible in cases where the cancer was 
confined to only one ovary. The 2018 ASCO recommendations note that ovarian cystectomy, a 
laparoscopic procedure typically done to remove ovarian cysts, can be performed for early-stage ovarian 
cancer (Oktay et al., 2018b). 
Other Potential Fertility Preservation Services  
Ovarian suppression for female breast cancer patients 
Gonadotropin-releasing hormone (GnRH) agonist (GnRHa) therapy is the use of a hormone that causes 
the ovaries to temporarily shut down during chemotherapy, thus potentially reducing damage to the 
follicles where eggs develop. This service is available to women who have completed puberty and is used 
in conjunction with chemotherapy, starting a week prior to chemotherapy and continuing for the course of 
chemotherapy treatment. GnRHa do not protect against radiation effects or from very aggressive forms of 
chemotherapy (Levine et al., 2010). The 2018 ASCO recommendations conclude that there is conflicting 
evidence that ovarian suppression using GnRH analogs are effective and that this approach should not 
be used in place of other proven methods; however, the guidelines also note that this therapy may be 
offered when other fertility preservation options are not available or for young women with breast cancer 
to reduce the likelihood of chemotherapy-induced ovarian insufficiency. The 2018 ASCO guidelines 
identify 5 of 7 medical association guidelines that recommend the use of GnRHa for fertility preservation 
in certain breast cancer patients (Oktay et al., 2018b). 
Experimental fertility preservation services 
The 2018 ASCO recommendations note that certain fertility preservation services are considered 
experimental: ovarian or testicular tissue cryopreservation and transplantation, in vitro follicle maturation 
(IVM) in females, and hormonal gonadoprotection in males (Oktay et al., 2018b). 
Ovarian tissue cryopreservation is the only option available for fertility preservation in prepubescent girls 
undergoing chemotherapy. In this experimental surgical procedure, ovarian tissue is removed and frozen. 
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This allows for the ovarian tissue to be thawed and reimplanted after the patient has finished with her 
treatment. The first ovarian transplant procedure was performed in 2000, and as of 2017, there had been 
at least 82 births as a result of this procedure (Jadoul et al., 2017). A 2017 meta-analysis including 8 
studies reported a combined live birth and ongoing pregnancy rate of 37.7% per woman undergoing 
ovarian tissue cryopreservation and transplantation and desiring pregnancy (Pacheco and Oktay, 2017). 
Based on recent data, the 2018 ASCO recommendations note that although this procedure is still 
considered experimental, emerging data may prompt reconsideration in the future, especially given the 
lack of current nonexperimental fertility preservation options for prepubescent females (Oktay et al., 
2018b).  
Testicular tissue cryopreservation is an outpatient surgical procedure where tissue is surgically removed 
and frozen. It is available for males either before or after puberty, but it is the main option for 
prepubescent males. This method has not yet produced any live births (Lee et al., 2006; Levine et al., 
2010; Loren et al., 2013; Onofre et al., 2016).  
In vitro follicle maturation (IVM) is used when fertility-threatening treatment is needed immediately, and it 
is not possible to delay treatment in order to collect mature oocytes without ovarian stimulation. In this 
case, immature oocytes are collected and matured outside of the body. There are preliminary data to 
suggest that IVM may be a feasible alternative for women, but as of 2017, only a few live births had been 
reported as a result of this procedure (Creux et al., 2017). One retrospective study including women with 
cancer undergoing either conventional IVF (n = 187 cycles) or IVM (n = 207 cycles) found that only 7% of 
women in the conventional IVF group (n = 19 cycles) and 10% in the IVM group (n = 14) returned to use 
the preserved oocytes or embryos. Of women using the preserved oocytes or embryos, the study found 
no difference in oocyte or embryo survival rates by procedure. However, IVM resulted in a significantly 
lower implantation rate (3.7% vs. 21.9% for conventional IVF) and fewer live births per embryo transfer 
(7.1% vs. 31.6% for conventional IVF), and the proportion of miscarriages was higher in the IVM group 
(50% vs. 16.7%) (Creux et al., 2018).  
GnRH analogs or antagonists are an experimental hormonal therapy that causes the testicles to 
temporarily shut down during chemotherapy, thus potentially causing a reduction in the damage to the 
sperm. The efficacy of this testicular hormonal suppression has only been evaluated in very small studies 
and is considered experimental (Lee et al., 2006; van der Kaaij et al., 2010). It is not endorsed by the 
recent ASCO recommendations (Oktay et al., 2018b). 
Fertility Preservation for Individuals With Autoimmune Rheumatic Disorders 
A systematic review of males with rheumatic diseases such as systemic lupus erythematosus and 
rheumatoid arthritis was conducted in 2016 by Tiseo and colleagues. A total of 19 articles were identified 
that addressed impaired fertility among males undergoing treatments for rheumatic diseases. The authors 
concluded that although these treatments had the potential to reduce fertility, permanent infertility was 
rare (Tiseo et al., 2016). Similarly, research among women undergoing treatments for autoimmune 
rheumatic disorders has found that newer medications that are safe to use during pregnancy can be 
utilized, instead of fertility-impairing medications, to improve changes of pregnancy without harm (Tincani 
et al., 2016).  
Fertility Preservation for Transgender Individuals and Individuals With Differences in Sex 
Development 
A national working group on fertility preservation for individuals with gender and sex diversity was 
convened in November of 2015 (Finlayson et al., 2016). This discussion centered around two groups: 
individuals whose gender identity is incongruent with their birth-assigned sex (i.e., transgender) and 
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individuals who have differences in sex development (DSD) where the reproductive organs do not 
develop as expected given their male or female chromosomes. For those who are postpubertal, standard 
options for maintaining fertility include sperm, oocyte or embryo cryopreservation. Transgender and DSD 
individuals who are prepubescent only have fertility preservation options available to them that are 
considered experimental. Transgender individuals face challenges in preserving their fertility in that the 
optimal time period for harvesting oocytes or sperm for cryopreservation is prior to initiation of hormone 
therapy but after reaching sexual maturity. This generally requires the patient to delay gender-affirming 
hormone treatment.  
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BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS 
As discussed in the Policy Context section, SB 600 would require DMHC-regulated health plans and CDI-
regulated policies to cover medically necessary expenses for standard fertility preservation services when 
a medically necessary treatment may directly or indirectly cause iatrogenic infertility.  
This section reports the potential incremental impacts of SB 600 on estimated baseline benefit coverage, 
utilization, and overall cost. CHBRP’s approach and key assumptions for this analysis are described 
below: 
• SB 600 states that the coverage of fertility preservation services be consistent with how “standard 
fertility preservation services” are defined by established medical practices and professional 
guidelines published by ASCO, ASRM, or other reputable professional organizations. According 
to ASCO and ASRM, cryopreservation of sperm, mature oocytes, and embryos falls under the 
definition of standard fertility preservation services.31 Other standard fertility preservation services 
that do not involve cryopreservation, such as ovarian transposition, are all covered by insurance 
as part of standard cancer treatment. Cryopreservation is not generally covered by insurance as 
part of standard cancer treatment. Hence, in this analysis, CHBRP focused on examining 
specifically the coverage of cryopreservation of sperm, mature oocytes, and embryos among 
enrollees in DMHC-regulated health plans and CDI-regulated policies in California.  
• Claims data from MarketScan database, could not be used to obtain utilization estimates because 
there are too few claims for cryopreservation use among enrollees with a cancer diagnosis to 
make robust estimates of utilization for this population. Thus, CHBRP estimated utilization of 
cryopreservation, both for baseline and postmandate, using cancer incidence rates grouped by 
sex, the peer-reviewed literature, and input from CHBRP’s content expert. Details regarding these 
assumptions are presented in Appendix C. 
• In its analysis, CHBRP included the top 10 types of cancer whose treatments pose the highest 
iatrogenic infertility risk. Cryopreservation utilization rates were assumed to be consistent across 
all types of cancer. Cancer incidence rates for reproductive age Californians were estimated 
using cancer statistics data from the 2015 Center for Disease Control and Prevention’s WONDER 
Database on males 10 to 49 years of age and females 10 to 44 years of age in California (see the 
Background section).  
• CHBRP estimated the unit costs of cryopreservation services for sperm, mature oocytes, and 
embryos based on 2016 MarketScan and Milliman’s proprietary 2016 Consolidated Health Cost 
Guidelines Sources Database (CHSD). The data were limited to California enrollees and further 
refined to identify only enrollees with a cryopreservation procedure. Medical and surgical services 
and drugs related to fertility preservation occurring prior to the cryopreservation were included 
and services after the cryopreservation were excluded.  
For further details on the underlying data sources and methods used in this analysis, please see 
Appendix C. 
                                                     
31 As noted in the Medical Effectiveness section, the 2018 ASCO recommendations conclude that there is conflicting 
evidence that ovarian suppression using GnRH analogs are effective and that this approach should not be used in 
place of other proven methods; however, the guidelines also note that this therapy may be offered when other fertility 
preservation options are not available or for young women with breast cancer to reduce the likelihood of 
chemotherapy-induced ovarian insufficiency. CHBRP does not include utilization of GnRHa in the cost impact 
analysis.  
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Baseline and Postmandate Benefit Coverage 
Current coverage of cryopreservation was determined by a survey of the largest (by enrollment) providers 
of health insurance in California. Responses to this survey represent 53% of enrollees with private market 
health insurance that can be subject to state mandates. SB 600 does not apply to Medi-Cal Managed 
Care enrollees.  
Currently, 0.9% of enrollees with health insurance that would be subject to SB 600 have coverage for 
cryopreservation services for sperm, mature oocytes, and embryos. Postmandate, the coverage for 
cryopreservation would increase to 100% based on the CHBRP assumption that all noncompliant plans 
and policies at baseline would become compliant postmandate (see estimate in Table 1).   
Baseline and Postmandate Utilization 
To determine the baseline utilization, CHBRP analyzed incidence rates of the top 10 cancers with 
treatments that pose the highest iatrogenic infertility risk (see the Background section). These incidence 
rates represent the population with newly diagnosed cancers annually, which CHBRP assumes is the 
population that would potentially seek and use cryopreservation. Out of the 16.9 million enrollees with 
coverage subject to the bill, the total number of enrollees of reproductive age with a new cancer diagnosis 
(2,553 males and 3,799 females) would remain constant from baseline to postmandate.  
Among this population, the baseline total proportion using fertility preservation services was derived using 
the findings from a study of the use of fertility preservation among cancer survivors when they underwent 
treatment for cancer and at risk of iatrogenic infertility (Bann et al., 2015).32  CHBRP applied findings from 
the study by Bann et al. (2015), data from the 2017 Society for Reproductive Technology33, and content 
expert input to estimate baseline utilization for enrollees with and without coverage CHBRP estimates 
postmandate utilization increases to the level of those enrollees who had coverage at baseline plus an 
additional 10% increase in utilization due to increased awareness, increased provider and enrollee 
knowledge of coverage, and a corresponding greater willingness to discuss fertility preservation options 
(Vindrola-Padros et al., 2017) that might occur with the passage SB 600.34  
Postmandate, no enrollees would use cryopreservation without coverage. CHBRP estimates that in the 
first year postmandate, SB 600 would result in 792 males and 961 female enrollees with cancer using 
cryopreservation services postmandate. Of the 792 male users postmandate, 136 enrollees would be 
new users of sperm cryopreservation. The estimated 639 male cryopreservation users at baseline using 
cryopreservation without coverage would experience financial relief postmandate as coverage would be 
available to them. Of the 961 female users postmandate, 516 enrollees would be new users (123 new 
users of embryo cryopreservation and 392 new users of mature oocyte cryopreservation). A total of 428 
female enrollees (102 users of embryo cryopreservation and 326 of mature oocyte cryopreservation) will 
                                                     
32 In the study by Bann et al (2015), of the 812 survey respondents living in the U.S. with complete data on fertility 
preservation and gender, 264 reported no interest in having any/any more children, thus approximately 70% of the 
final sample of participants (550) in the study were interested in having a child. Among the final sample, 49% of male 
and 22% of female cancer survivors took steps to preserve fertility. CHBRP additionally assumed females would be 
twice as likely to forgo steps to pursue cryopreservation than males due to the higher cost of oocyte ($10,078) and 
embryo ($11,254) cryopreservation compared to sperm cryopreservation ($468). 
33 In 2017, 23% of utilization of female cryopreservation was for embryos and 775 for mature oocytes. 
34 Studies of utilization change over time due to the passage of fertility preservation legislation do not exist; the 10% 
increase is an assumed based on implications of findings in Vindrola-Padros et al (2017) and CHBRP’s content 
expert. 
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use cryopreservation with coverage postmandate, whereas they were using the services without 
coverage at baseline.  
Baseline and Postmandate Per-Unit Cost  
Using claims from the 2016 CHSD and MarketScan, CHBRP estimates that the per-unit cost of fertility 
preservation services averages $468 for sperm cryopreservation and $11,254 for embryo 
cryopreservation and $10,078 for mature oocyte cryopreservation. These unit costs include medical, 
surgical, and drug costs related to retrieving and preserving sperm, oocytes, and embryos, culturing of 
oocytes and embryos, and storage for 1 year. Female fertility preservation services have a higher 
average unit cost due to increased costs for harvesting the reproductive oocytes, because it is a surgical 
procedure for females and a nonsurgical procedure for males. The higher average unit cost for females 
also includes the common procedure, when applicable, of harvesting sperm from a spouse through the 
same insurance coverage. CHBRP assumes unit costs for these cryopreservation services/procedures 
would not change from baseline to postmandate.  
Baseline and Postmandate Expenditures 
SB 600 would increase net annual expenditures by total net annual $6,773,000 or total net annual 
0.0043% for enrollees with DMHC-regulated plans and CDI-regulated policies.  
Premiums 
Changes in premiums as a result of SB 600 would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 1, Table 5, and Table 6), with health insurance that would 
be subject to SB 600. The largest increases are in the individual markets for CDI-regulated policies 
(0.008%) and DMHC-regulated plans and products (0.01%); the smallest increases in premiums are in 
the CDI-regulated large group policies (0.003%). Among publicly funded DMHC-regulated CalPERS 
HMOs, the premium increase is about 0.009%.  
Enrollee Expenses 
SB 600–related changes in enrollee expenses for covered benefits (deductibles, copays, etc.) and 
enrollee expenses for noncovered benefits would vary by market segment. Note that such changes are 
related to the number of enrollees with health insurance that would be subject to SB 600 expected to use 
the relevant fertility preservation services in the first year after enactment. Enrollee expenses for 
noncovered benefits would decrease by about $0.02 for all plans. The decrease in expenditures for 
noncovered benefits for CalPERS HMOs is $0.022. An increase in enrollee expenses for covered benefits 
(i.e., how much enrollees pay for services that would be covered postmandate) would also occur as 
enrollees gain coverage, ranging from $0.014 for DMHC-regulated large group plans to $0.026 for CDI-
regulated small group plans. The increase in expenditures for covered benefits for CalPERS HMOs is 
$0.004 (see Table 3). 
Out-of-Pocket Spending for Covered and Noncovered Expenses 
CHBRP estimates that for newly covered enrollees, expenses for noncovered cryopreservation 
postmandate would be reduced by $4,734,000 overall and an increase in expenses for covered benefits 
(via co-payments, for example) of $3,244,000 (Table 1).  
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CHBRP estimates are based on claims data that reflect charges to carriers for cryopreservation services. 
It may underestimate the costs for enrollees due to carriers’ ability to negotiate discounted rates that are 
unavailable to patients and their families. The rates paid by patients for noncovered services may be as 
much as 40% greater than the rates reflected in this analysis.  
According to CHBRP’s carrier survey responses, about 10% of enrollees in the nongrandfathered large 
group and 100% of enrollees in the Covered California individual markets with coverage for 
cryopreservation have the same cost structure as major medical services. CHBRP assumes the cost-
sharing structure for cryopreservation will involve a 50% coinsurance, based on responses to the carrier 
surveys, for all other enrollees. Because SB 600 does not specify requirements regarding cost sharing or 
coinsurance, CHBRP assumes carriers would cover cryopreservation with the same cost-sharing 
structure as seen at baseline. For enrollees with cancer using treatment that can cause iatrogenic 
infertility and using cryopreservation, SB 600 would result in varied impacts on out-of-pocket costs for 
covered cryopreservation. As noted in Table 4 below, cost-sharing impacts (not including premiums) 
among enrollees using cryopreservation would range from $184 for CalPERS HMO enrollees to $1,051 
for enrollees in small group plans. 
Table 4. Cost-Sharing Impact of SB 600 Among Enrollees Diagnosed With Cancer That May Result in 
Iatrogenic Infertility 
  
Large 
Group 
Small 
Group 
Individual 
CalPERS 
HMO 
% of enrollees with cost-sharing impact from SB 600* 0.03% 0.03% 0.03% 0.03% 
Average annual cost sharing for cryopreservation 
services among impacted members* 
$611.32 $1,051.21 $575.65 $184.44 
Source: California Health Benefits Review Program, 2019. 
Notes: *Not including impacts on premiums. 
Key: CalPERS HMO = California Public Employees’ Retirement System Health Maintenance Organization. 
 
Potential Cost Offsets or Savings in the First 12 Months After Enactment 
CHBRP does not anticipate any cost offsets or savings in the first year postmandate, because fertility 
preservation services do not correspond to any reduction in use of infertility services during the first year. 
As discussed in the Public Health Impacts section in greater detail below, studies have suggested 
potential delays in cancer treatment due to the use of fertility preservation, however no studies reported 
an increased risk of mortality for the cancer patients (Baynosa et al., 2009; Madrigrano et al., 2007; 
Waimey et al., 2015). 
Postmandate Administrative Expenses and Other Expenses 
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-
regulated policies would remain proportional to the increase in premiums. CHBRP assumes that if health 
care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding 
proportional increase in administrative costs, which are passed on to consumers in the form of increased 
premiums. CHBRP assumes that the administrative cost proportion of premiums is unchanged. All health 
plans and insurers include a component for administration and profit in their premiums. 
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Other Considerations for Policymakers 
In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations 
for policymakers are discussed below. 
Potential Cost of Exceeding Essential Health Benefits 
As explained in the Policy Context section it is unclear whether this bill would exceed essential health 
benefits (EHBs).  
Postmandate Changes in the Number of Uninsured Persons35 
As the change in average premiums does not exceed 1% for any market segment (see Table 6), CHBRP 
would expect no measurable change in the number of uninsured persons due to the enactment of SB 
600. 
Changes in Public Program Enrollment 
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly 
funded insurance programs due to the enactment of SB 600. 
How Lack of Benefit Coverage Results in Cost Shifts to Other Payers 
Foundation support (particularly the Livestrong Foundation) has assisted in reducing the cost of fertility 
preservation services for either: (1) enrollees who do not have benefit coverage in cases of potential 
iatrogenic infertility due to cancer treatment, or (2) people who are completely uninsured. In general, a 
subsidy reduces costs for women to $3,000, which is then paid for out of pocket by the enrollee 
(Livestrong, 2017). No other payers have been affected by the lack of benefit coverage. 
                                                     
35 See also CHBRP’s Uninsured: Criteria and Methods for Estimating the Impact of Mandates on the Number of 
Individuals Who Become Uninsured in Response to Premium Increases (December 2015), available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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Table 5. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under 65) 
(c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 600 10,565,000 3,099,000 2,184,000 
 
523,000 0 0 
 
318,000 108,000 102,000 
 
16,899,000 
Premiums              
 
Average portion 
of premium paid 
by employer $555.35 $341.99 $0.00  $493.71 $268.13 $694.55  $710.92 $462.84 $0.00  $118,029,198,000 
 
Average portion 
of premium paid 
by employee $39.66 $205.44 $437.39  $94.04 $0.00 $0.00  $250.37 $202.64 $475.67  $26,521,718,000 
 Total premium $595.01 $547.43 $437.39  $587.76 $268.13 $694.55  $961.29 $665.48 $475.67  $144,550,916,000 
Enrollee expenses                 
 
For covered 
benefits 
(deductibles, 
copays, etc.) $46.18 $121.03 $115.38  $48.33 $0.00 $0.00  $162.44 $186.84 $168.51  $14,750,880,000 
 
For noncovered 
benefits (e) $0.02 $0.02 $0.02  $0.02 $0.00 $0.00  $0.02 $0.02 $0.02  $4,734,000 
 
Total 
expenditures $641.22 $668.49 $552.80  $636.10 $268.13 $694.55  $1,123.75 $852.34 $644.20  $159,306,530,000 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
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(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance.  This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.36  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
36 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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Table 6. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under  
65) (c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 600 10,565,000 3,099,000 2,184,000 
 
523,000 0 0 
 
318,000 108,000 102,000 
 
16,899,000 
Premiums              
 
Average portion of 
premium paid by 
employer $0.0385 $0.0208 $0.0000  $0.0432 $0.0000 $0.0000  $0.0229 $0.0224 $0.0000  $6,039,000 
 
Average portion of 
premium paid by 
employee $0.0027 $0.0125 $0.0484  $0.0082 $0.0000 $0.0000  $0.0081 $0.0098 $0.0402  $2,225,000 
 Total premium $0.0412 $0.0333 $0.0484  $0.0514 $0.0000 $0.0000  $0.0309 $0.0323 $0.0402  $8,263,000 
Enrollee expenses              
 
For covered 
benefits 
(deductibles, 
copays, etc.) $0.0138 $0.0252 $0.0149  $0.0042 $0.0000 $0.0000  $0.0224 $0.0258 $0.0210  $3,244,000 
 
For noncovered 
benefits (e) -$0.0228 -$0.0242 -$0.0249  -$0.0224 $0.0000 $0.0000  -$0.0227 -$0.0241 -$0.0247  -$4,734,000 
 
Total 
expenditures $0.0322 $0.0342 $0.0384  $0.0333 $0.0000 $0.0000  $0.0306 $0.0339 $0.0365  $6,773,000 
Percent change              
 Premiums 0.0069% 0.0061% 0.0111%  0.0087% 0.0000% 0.0000%  0.0032% 0.0048% 0.0084%  0.0057% 
 
Total 
expenditures 0.0050% 0.0051% 0.0069%  0.0052% 0.0000% 0.0000%  0.0027% 0.0040% 0.0057%  0.0043% 
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Source: California Health Benefits Review Program, 2019. 
Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance.  This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.37  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
 
                                                     
37 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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PUBLIC HEALTH IMPACTS 
As discussed in the Policy Context section, SB 600 would mandate coverage of medically necessary 
expenses for standard fertility preservation services when a medically necessary treatment may directly 
or indirectly cause iatrogenic infertility, and defines iatrogenic infertility, medical treatment that causes 
iatrogenic infertility, standard fertility preservation services, and medical necessity. 
The public health impact analysis estimates the short-term impacts (within 12 months of implementation) 
of SB 600 on quality of life, potential harms from fertility preservation treatment, financial burden, and the 
impact on potential disparities by sex, race/ethnicity, and sexual orientation. See the Long-Term Impacts 
section for estimates of birth outcomes for men and women using cryopreserved sperm, oocytes, or 
embryos obtained through fertility preservation and for discussion of the health of the subsequent 
children. 
Estimated Public Health Outcomes 
The section focuses on three services: sperm cryopreservation, oocyte (egg) cryopreservation, and 
embryo cryopreservation (freezing of embryos). This section does not address the remaining standard of 
care fertility preservation services (ovarian transposition, ovarian and testicular shielding during radiation 
therapy, conservative gynecologic surgery, and radical trachelectomy) because CHBRP assumes that 
these services would already be covered by state-regulated plans and policies (see Error! Reference s
ource not found.for more information).  
As presented in the Medical Effectiveness section, there is a preponderance of evidence for sperm, 
oocyte, and embryo cryopreservation are effective methods of fertility preservation.  
The Benefit Coverage, Cost, and Utilization Impacts section estimates that 0.9% of enrollees with health 
insurance subject to SB 600 have coverage for fertility preservation at baseline with 6,352 cancer patients 
at risk of iatrogenic infertility. The number of cancer patients remains the same postmandate; however, 
the number using fertility preservation services would increase from 1,102 enrollees to 1,753 enrollees in 
the first year postmandate.  
Quality of Life 
Loss of fertility can negatively impact the quality of life for cancer survivors of reproductive age, including 
unresolved grief, depression, and anxiety (Lawson et al., 2015; Lee et al., 2006; Wallace et al., 2005). For 
instance, a survey of breast cancer patients of reproductive age documented that 57% were very or 
somewhat concerned about their fertility (Partridge et al., 2004). Distress regarding iatrogenic infertility 
can persist for many years, as demonstrated by one study that contacted women 10 years after they 
received cancer treatment and found that childless women had a statistically significant increase in 
distress and more intrusive thoughts about infertility than those who had at least one biological child or 
adopted or had stepchildren (Canada and Schover, 2012). 
A systematic review identified 47 articles focused on the psychosocial and quality-of-life effects on female 
cancer patients undergoing fertility preservation. It concluded that those who received counseling and 
services (for those who chose fertility preservation) experienced reduced regret and dissatisfaction about 
fertility outcomes (Deshpande et al., 2015). A literature review including 24 articles about fertility 
preservation decision-making reported similar conclusions; decisional regret or uncertainty was greatly 
reduced for those with better fertility knowledge regardless of patient choice to use the service or not (Li 
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et al., 2016). 
 
In the first year postmandate, SB 600 would likely improve the quality of life by reducing regret about 
fertility outcomes, dissatisfaction, and distress for the additional 651 enrollees newly using fertility 
preservation services to treat iatrogenic infertility.   
Barriers to Fertility Preservation Services 
Patients and providers face different barriers to obtaining fertility preservation services. A literature review 
by Panagiotopoulou et al. (2018) reported that, frequently, newly diagnosed patients were overwhelmed 
with handling their cancer diagnosis and, therefore, were unable to process fertility-related information. 
Some survivors also reported that fertility issues were not addressed or inadequately addressed by 
providers, which led to decision regret by survivors. Patients also reported concerns about delays in 
cancer treatment to preserve fertility, moral dilemmas, and offspring health as barriers to seeking fertility 
preservation. Another barrier was the absence of health insurance coverage because the out-of-pocket 
cost of fertility preservation was considered prohibitive by many patients. All these barriers were reported 
more often by females than males. Gaps in obtaining fertility preservation counseling and services (care 
coordination) were also problematic for some cancer patients.  
The literature review also reported barriers posed or experienced by providers. For example, multiple 
studies found that providers were less likely to counsel certain patients about fertility preservation based 
on a patient’s age (older), gender (female), relationship status (unmarried), sociocultural background, and 
perceived lack of willingness to self-fund fertility preservation. Providers also reported language barriers 
and incomplete knowledge of fertility preservation and referral networks as barriers to discussions about 
fertility preservation (Adams et al., 2013; Miller et al., 2014; Nahata et al., 2017b; Panagiotopoulou et al., 
2018).  
Perhaps most relevant to SB 600 are study findings regarding provider perception of cost of fertility 
preservation. A systematic review about health care professionals’ discussions of fertility preservation 
with cancer patients found five studies concluding that providers did not discuss fertility preservation with 
young patients if they thought they could not afford treatment costs (Vindrola-Padros et al., 2017).  
SB 600 could potentially increase the rate of physician referrals for fertility counseling and preservation by 
providing coverage for such services and reducing out-of-pocket costs for patients experiencing 
iatrogenic infertility. Broader insurance coverage might also remove cost as a provider-perceived barrier. 
Impact on Disparities38 
Insurance benefit mandates that bring more state-regulated plans and policies to parity may change an 
existing disparity.Error! Bookmark not defined. As described in the Error! Reference source not fo
und. section, there is limited evidence of differences in fertility preservation counseling and utilization by 
race/ethnicity, sex, and gender identity; however, the extent to which these differences result from 
disparities is unknown.  
                                                     
38. For details about CHBRP’s methodological approach to analyzing disparities, see the Benefit Mandate Structure 
and Unequal Racial/Ethnic Health Impacts document here: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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Impact on Racial/Ethnic Disparities 
As presented in the Error! Reference source not found. section, several studies report that racial and e
thnic disparities may exist with respect to provider discussions regarding infertility risks, fertility 
preservation options and referrals for fertility preservation services. However, findings from these studies 
were not statistically significant and were of insufficient quality to conclude whether racial/ethnic minorities 
were more likely than whites to experience barriers to access or poorer fertility preservation outcomes.  
The extent of racial or ethnic disparities in the use of or outcomes related to fertility preservation for 
iatrogenic infertility is unknown due to a lack of evidence. Therefore, although limited evidence finds 
fertility preservation for patients with iatrogenic infertility medically effective, the impact of SB 600 on 
potential racial/ethnic disparities is unknown. 
Impact on Disparities by Sex 
Gender differences in rates of cancer and the cost of fertility preservation are notable. For instance, there 
are almost twice as many California females as males of reproductive age who have cancer with 
treatments likely to produce iatrogenic infertility (due primarily to the high incidence of breast cancer in 
females). For males, sperm cryopreservation is the standard method of preserving fertility, costing 
approximately $468. For females, the standard fertility preservation methods average an estimated 
$10,666, or about 23 times the cost that males incur. CHBRP estimates that, in the first year 
postmandate, SB 600 would reduce cost-sharing for noncovered services  for 428 females by more than 
$4.4 million in uncovered treatment costs, whereas 639 males would see a reduction of about $300,000 
in uncovered costs. However, enrollees would still be responsible for the cost-sharing determined by their 
insurer, which may be as high as 50% for covered services.  
Gender disparities exist in both counselling for and use of fertility preservation services. Evidence in the 
Error! Reference source not found. section indicates that males are more likely to be referred for f
ertility preservation services than females. This may be partially due to physician reluctance to address 
fertility preservation with certain patients because of provider-perceived prohibitive costs 
(Panagiotopoulou et al., 2018). Higher fertility preservation utilization by males was reported in another 
study, which found that 33% of young adult cancer survivors used fertility preservation services, with 
males more than twice as likely than females to use services (49% and 22%, respectively) (Bann et al., 
2015). 
The Bann et al. (2015) study also reported on those survivors who did not use fertility preservation 
services. More women than men (33% and 28%, respectively) reported a lack of information as a key 
reason (defined as not enough information about their fertility risk; availability of fertility preservation 
options; and how to obtain those services). This finding is consistent with other studies reporting that 
more men receive counseling and referral than women (Nahata et al., 2017b; Panagiotopoulou et al., 
2018). Bann et al. (2015) also cite other reasons for declining fertility preservation including not enough 
time before cancer treatment (women 39%; men 25%) and cost (women 24%; men 27%). Of these self-
reported reasons, SB 600 could remove or reduce the cost barrier, which could increase utilization for 
both genders. 
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In California, females have twice the rate of cancers with treatments causing iatrogenic infertility as 
males; furthermore, females pay 23 times more for uncovered fertility preservation services than males.  
Postmandate, SB 600 would decrease the gender disparity by reducing financial burden thereby bringing 
costs between genders to parity, and reduce the cost consideration from her decision-making process 
regarding iatrogenic infertility risk. However, CHBRP estimates that some females would still face greater 
out-of-pocket expense burdens than males, postmandate, due to differences in costs of sex-specific 
preservation methods (e.g., more office visits, prescription drug cost). 
Impact on the Transgender Population and Individuals with Differences in Sex 
Development 
As presented in the Error! Reference source not found. section, transgender persons undergoing g
ender confirmation surgery or hormonal treatment will experience iatrogenic infertility. Furthermore, a 
portion of those individuals are likely interested in future parenthood, and according to the American 
Society for Reproductive Medicine, should be informed about and offered fertility preservation services to 
retain their ability to reproduce following gonadotoxic treatment (and would be eligible for coverage under 
SB 600) (ASRM, 2015). However, there is insufficient literature to understand whether disparities for this 
population exist regarding fertility preservation access, utilization, and outcomes as compared with other 
populations experiencing iatrogenic fertility. 
CHBRP projects that SB 600 would provide fertility preservation coverage for an unknown number of 
newly covered enrollees who will experience iatrogenic infertility due to gender confirmation treatments, 
thus reducing any potential disparities in access to care.  
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LONG-TERM IMPACTS 
Long-term utilization are expected to remain constant with the findings of year 1 and year 2 projections, 
assuming that the number of enrollees in DMHC-regulated plans or CDI-regulated policies remains 
constant along with the costs of fertility preservation services and infertility treatments. 
Long-Term Utilization and Cost Impacts 
Utilization Impacts  
Postmandate, CHBRP estimates that SB 600 would increase utilization of cryopreservation services 
among enrollees with cancer by an additional people 123 using embryo cryopreservation, 392 using 
mature oocyte cryopreservation, and 136 using sperm cryopreservation during the first year. This 
estimate is based on an annual incidence rate of the top 10 cancers, which will likely remain constant per 
annum over the long term as long as the incidence rates also remain constant. It must be noted, however, 
that the demand for fertility preservation services is dependent on the wishes of the patient, and those 
who do not wish to have future children will dampen demand. In the long term, use of cryopreservation 
will lead to some increased utilization of infertility services to achieve pregnancy among the affected 
enrollees.  
Cost Impacts 
Although SB 600 would decrease the financial burden of fertility preservation services for enrollees in the 
short term, SB 600 would not cover future storage costs or assisted reproductive technology that is 
required to achieve pregnancy; those who retrieve cryopreserved sperm, oocytes, or embryos would likely 
pay out of pocket for assisted reproductive technology to become pregnant. The cost of cryopreservation 
— retrieval and storage— may change over time as technology advances are introduced to this industry. 
It is possible that technological advances will reduce the cost of cryopreservation in the future, but it is 
unclear whether these technologies are on the horizon or how they will impact overall expenditures for 
cryopreservation.  
CHBRP estimates that SB 600 would increase health care costs by 0.0043%, based on the utilization of 
fertility preservation services in year 1. As mentioned above, excluded from the cost estimates were the 
infertility services that will be needed to implant the frozen embryos, or perform IVF with oocytes or 
sperm, and enable enrollees with iatrogenic infertility due to cancer to become parents. CHBRP assumes 
that the use of cryopreserved sperm, oocytes, and embryos is likely to occur in the future after 
chemotherapy treatment is complete and the enrollee is at a stage of life where they are ready to have a 
child. When the enrollee is ready to use the cryopreserved material at some point in the future, they 
would incur costs associated with infertility treatment. Costs for this treatment incurred by the enrollee 
would be dependent on whether or not infertility is covered by insurance and the level of coverage. Age of 
final attempt at pregnancy also can influence the long-term cost impacts. One study found oocyte 
preservation before age 35 years by women planning to defer pregnancy attempts until age 40 would 
decrease cost per live birth to $39,946 (and increase odds of live birth to 62% by the end of the model), 
compared to the cost per live birth of $55,060 (and 42% chance of live birth) for women over 40 who did 
not undergo oocyte preservation (Devine et al., 2015). It is possible, therefore, that the costs for 
pregnancy among women undergoing fertility preservation would be lower in the long term compared to 
the general population, due to preserving eggs of better quality when they were younger. 
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Long-Term Public Health Impacts 
When possible, CHBRP estimates the long-term effects (beyond 12 months postmandate) to the public’s 
health that would be attributable to the legislation, including impacts on social determinants of health, 
premature death, and economic loss. In the case of SB 600, enrollees with iatrogenic infertility may 
choose to conceive once the acute phase of their illness is over (Waimey et al., 2015). CHBRP estimates 
the number of live births associated with retrieving frozen sperm, oocytes, or embryos obtained during the 
fertility preservation phase of care.   
Long-Term Impacts on Public Health: Deliveries/Births 
Males 
CHBRP estimates that an additional 136 males would use sperm cryopreservation annually as a result of 
SB 600. Johnson et al. (2013) reported that over a 20-year period, 9.5% of 378 male cancer survivors 
retrieved frozen sperm for reproductive purposes. The study’s long time period for retrieval is a good 
representation of the varied timeframe in which males might retrieve sperm, and includes those who may 
have been adolescents or very young adults when storing sperm originally. Using these retrieval rates, in 
the case of SB 600, about 13 males undergoing fertility preservation in a given year would eventually 
retrieve cryopreserved sperm to reproduce. As reported in the Error! Reference source not found. s
ection, the birth rate using cryopreserved sperm is 49% (Stefania Ferrari et al., 2016). Thus, CHBRP 
estimates that 6 births would occur in the original cohort of 136 males newly using fertility preservation in 
a given year. Note that more than one cycle of artificial insemination or IVF may be required to achieve 
pregnancy followed by live birth. 
For each cohort of males seeking fertility preservation for iatrogenic infertility in a given year, CHBRP 
estimates the long-term marginal impact of SB 600 would yield an estimated 6 more live births to these 
men and their partners over time. 
Females 
CHBRP estimates that an additional 515 females would use either embryo or oocyte cryopreservation 
annually as a result of SB 600. Although CHBRP found one single center study about differential use of 
oocyte and embryo cryopreservation (9.5% and 90.5%, respectively) (Cardozo et al., 2015), the method 
chosen by the patient is informed by clinical and personal factors such as type of cancer and treatment, 
age at cancer diagnosis, relationship status, and moral beliefs and values.  
Embryo cryopreservation is considered the most successful fertility preservation approach for females 
and the standard preservation method for women with a male partner (see Error! Reference source not f
ound. section), whereas oocyte cryopreservation may be more appropriate for those females without 
partners or who have a belief system at odds with storing embryos. CHBRP found one study reporting on 
live birth outcomes for cancer survivors using cryopreservation. Cardoza et al. (2015) report that over a 
17-year period, 33% of female cancer survivors retrieved frozen oocytes or embryos, 47% of which 
resulted in live births. In the case of SB 600, an estimated 170 females of the 515 women newly 
accessing fertility preservation services in the first year would eventually retrieve the frozen oocytes or 
embryos. The live birth rate is 47%; thus, about 80 live births from these retrievals would occur in the 
original cohort of 515 females newly using fertility preservation in the first year. Note that more than one 
IVF cycle may be required to achieve the live birth. 
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Note that these are estimates. As stated earlier, success in achieving live births is inversely associated 
with age, with the highest success rates in women under age 35 years and lowest success in women 
over age 40 years (SART, 2014). Also, this estimate assumes a minimum of one birth per couple, but 
some couples may choose to have several children over time or have twins or higher order multiples. 
Finally, the birth estimates do not represent live births per year; they represent deliveries that may occur 
over many years, depending upon when survivors retrieve cryopreserved sperm, oocytes, or embryos.  
For each cohort of females seeking fertility preservation for iatrogenic infertility in a given year, CHBRP 
estimates the long-term marginal impact of SB 600 would yield an estimated 80 more live births among 
these women over time.  
Potential Harms Associated With Cryopreservation and ART 
Those who use cryopreservation prior to gonadotoxic treatments and experience ongoing infertility must 
use assisted reproductive technology (ART) or artificial insemination to become pregnant using the 
cryopreserved materials. The literature contains little evidence regarding the long-term outcomes of 
cryopreservation. Cobo et al. (2014) reported that 1,027 babies were born from cryopreserved oocytes in 
2014 with no observed increase in congenital abnormalities.  
CHBRP reviewed harms of IVF and planned oocyte preservation for the April 2019 analysis AB 767 
Infertility. In summary, the preponderance of evidence shows that ART leads to some maternal harms, 
and to both maternal and offspring harms due to multiple gestation and pre-term delivery. CHBRP also 
noted, based on American Society of Reproductive Medicine’s Ethics Committee opinion on oocyte 
preservation, that oocyte preservation cannot be seen as a guarantee of future fertility (ASRM, 2018). 
Please see AB 767 Medical Effectiveness and Long-Term Impacts sections for full details. 
Evidence-based literature indicates that although there may be some risk of negative health outcomes for 
ART-conceived infants or to women undergoing ART overall, fertility preservation does not pose a higher 
risk to the health outcomes of children born from cryopreserved sperm, oocytes, or embryos from persons 
with iatrogenic infertility than those risks associated with assisted reproductive technology used to treat 
noniatrogenic infertility.  
  
Analysis of California Senate Bill 600 
Current as of April 17, 2019 www.chbrp.org A-1 
APPENDIX A  TEXT OF BILL ANALYZED 
On February 25, 2019, the California Senate Committee on Health requested that CHBRP analyze SB 
600. 
 
SENATE BILL No. 600 
 
Introduced by Senator Portantino 
 
February 22, 2019 
 
An act to add Sections 1374.551 and 1374.552 to the Health and Safety Code, and to add 
Sections 10119.61 and 10119.62 to the Insurance Code, relating to healthcare coverage. 
 
LEGISLATIVE COUNSEL'S DIGEST 
 
SB 600, as introduced, Portantino. Healthcare coverage: fertility preservation. 
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure 
and regulation of health care service plans by the Department of Managed Health Care and makes 
a willful violation of the act a crime. Existing law also provides for the regulation of health insurers 
by the Department of Insurance. Existing law requires every group health care service plan contract 
and health insurance policy issued, amended, or renewed on or after January 1, 2017, to include, 
at a minimum, coverage for essential health benefits, including medically necessary basic health 
care services, as defined. 
 
This bill would clarify that an individual or group health care service plan contract or health 
insurance policy that covers hospital, medical, or surgical expenses includes coverage for standard 
fertility preservation services when a medically necessary treatment may cause iatrogenic 
infertility to an enrollee or insured. The bill would state that these provisions are declaratory of 
existing law. 
 
This bill would also prohibit a health care service plan or health insurer from denying coverage for 
standard fertility preservation services based on medical necessity when a provider of a treatment 
of a medical condition authorized by the plan or policy states that the treatment may cause 
iatrogenic infertility to an enrollee or insured. Because a willful violation of these provisions by a 
health care service plan would be a crime, the bill would impose a state-mandated local program. 
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The California Constitution requires the state to reimburse local agencies and school districts for 
certain costs mandated by the state. Statutory provisions establish procedures for making that 
reimbursement. 
 
This bill would provide that no reimbursement is required by this act for a specified reason. 
 
DIGEST KEY 
Vote: majority   Appropriation: no   Fiscal Committee: yes   Local Program: yes   
 
BILL TEXT 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
SECTION 1. 
Section 1374.551 is added to the Health and Safety Code, to read: 
1374.551. (a) An individual or group health care service plan contract that covers hospital, 
medical, or surgical expenses includes coverage for medically necessary expenses for standard 
fertility preservation services when a medically necessary treatment may directly or indirectly 
cause iatrogenic infertility to an enrollee. 
(b) For purposes of this section and Section 1374.552, the following definitions apply: 
(1) “Iatrogenic infertility” means an impairment of fertility caused directly or indirectly by 
surgery, chemotherapy, radiation, or other medical treatment. 
(2) Medical treatment that “may directly or indirectly cause iatrogenic infertility” means medical 
treatment with a possible side effect of impaired fertility, as established by the American Society 
of Clinical Oncology, the American Society for Reproductive Medicine, or other reputable 
professional association or organization. 
(3) “Standard fertility preservation services” means procedures consistent with the established 
medical practices and professional guidelines published by the American Society of Clinical 
Oncology, the American Society for Reproductive Medicine, or other reputable professional 
medical organization. 
SEC. 2. Section 1374.552 is added to the Health and Safety Code, to read: 
1374.552. (a) Standard fertility preservation services shall be deemed medically necessary when 
a provider of treatment of a medical condition authorized by a health care service plan states that 
there is a substantial likelihood that the treatment may directly or indirectly cause iatrogenic 
infertility to the enrollee. 
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(b) When a provider states that standard fertility preservation services are medically necessary 
pursuant to subdivision (a), a health care service plan shall not deny coverage for those services 
based on medical necessity. 
SEC. 3. 
Section 10119.61 is added to the Insurance Code, to read: 
10119.61. (a) An individual or group health insurance policy that covers hospital, medical, or 
surgical expenses includes coverage for medically necessary expenses for standard fertility 
preservation services when a medically necessary treatment may directly or indirectly cause 
iatrogenic infertility to an insured. 
(b) For purposes of this section and Section 10119.62, the following definitions apply: 
(1) “Iatrogenic infertility” means an impairment of fertility caused directly or indirectly by 
surgery, chemotherapy, radiation, or other medical treatment. 
(2) Medical treatment that “may directly or indirectly cause iatrogenic infertility” means medical 
treatment with a possible side effect of impaired fertility, as established by the American Society 
of Clinical Oncology, the American Society for Reproductive Medicine, or other reputable 
professional association or organization. 
(3) “Standard fertility preservation services” means procedures consistent with the established 
medical practices and professional guidelines published by the American Society of Clinical 
Oncology, the American Society for Reproductive Medicine, or other reputable professional 
medical organization. 
SEC. 4. 
Section 10119.62 is added to the Insurance Code, to read: 
10119.62. (a) Standard fertility preservation services shall be deemed medically necessary when 
a provider of treatment of a medical condition authorized by a health insurance policy states that 
there is a substantial likelihood that the treatment may cause iatrogenic infertility to the insured. 
(b) When a provider states that standard fertility preservation services are medically necessary 
pursuant to subdivision (a), an insurer shall not deny coverage for those services based on 
medical necessity. 
SEC. 5. 
The addition of Section 1374.551 to the Health and Safety Code and Section 10119.61 to the 
Insurance Code by this act does not constitute a change in, but is declaratory of, existing law. 
 
Analysis of California Senate Bill 600 
Current as of April 17, 2019 www.chbrp.org A-4 
SEC. 6. 
No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California 
Constitution because the only costs that may be incurred by a local agency or school district will 
be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or 
changes the penalty for a crime or infraction, within the meaning of Section 17556 of the 
Government Code, or changes the definition of a crime within the meaning of Section 6 of 
Article XIII B of the California Constitution. 
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APPENDIX B  LITERATURE REVIEW METHODS 
This appendix describes methods used in the medical effectiveness literature review conducted for this 
report. A discussion of CHBRP’s system for grading evidence, as well as lists of MeSH Terms, publication 
types, and keywords, follows. 
Studies of the effects of fertility preservation services for patients at risk for iatrogenic infertility were 
identified through searches of PubMed, the Cochrane Library, and Web of Science. Websites maintained 
by the following organizations that produce and/or index meta-analyses and systematic reviews were also 
searched: the Agency for Healthcare Research and Quality (AHRQ), the International Network of 
Agencies for Health Technology Assessment (INAHTA), the National Health Service (NHS) Centre for 
Reviews and Dissemination, the National Institute for Health and Clinical Excellence (NICE), and the 
Scottish Intercollegiate Guideline Network.  
The search was limited to studies published since 2017 to the present because CHBRP had previously 
conducted thorough literature searches on these topics in 2011, 2013, and 2017 for Assembly Bill (AB) 
428, SB 912, and SB 172, respectively. The search was limited to abstracts of studies published in 
English. Of the 360 articles found in the literature review, 31 were reviewed for potential inclusion in this 
report on SB 600, and a total of 4 studies were included in the medical effectiveness review for this 
report, in addition to those identified as part of previous CHBRP reviews. The other articles were 
eliminated because they did not focus on patients undergoing fertility preservation due to cancer 
treatment or reported findings from case reports or case series, which are considered to be low quality in 
CHBRP’s hierarchy of evidence due to their high risk of bias (California Health Benefits Review Program, 
2019). The other articles were eliminated because they were not limited to patients undergoing fertility 
preservation due to cancer treatment or were case reports or case series, which are considered to be low 
quality in CHBRP’s hierarchy of evidence due to their high risk of bias (California Health Benefits Review 
Program, 2019).  
Evidence Grading System 
In making a “call” for each outcome measure, the medical effectiveness lead and the content expert 
consider the number of studies as well the strength of the evidence. Further information about the criteria 
CHBRP uses to evaluate evidence of medical effectiveness can be found in CHBRP’s Medical 
Effectiveness Analysis Research Approach.39 To grade the evidence for each outcome measured, the 
team uses a grading system that has the following categories: 
• Research design; 
• Statistical significance; 
• Direction of effect;  
• Size of effect; and 
• Generalizability of findings.  
The grading system also contains an overall conclusion that encompasses findings in these five domains. 
The conclusion is a statement that captures the strength and consistency of the evidence of an 
intervention’s effect on an outcome. The following terms are used to characterize the body of evidence 
regarding an outcome: 
                                                     
39 Available at: http://chbrp.com/analysis_methodology/medical_effectiveness_analysis.php. 
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• Clear and convincing evidence; 
• Preponderance of evidence; 
• Limited evidence 
• Inconclusive evidence; and  
• Insufficient evidence. 
A grade of clear and convincing evidence indicates that there are multiple studies of a treatment and that 
the large majority of studies are of high quality and consistently find that the treatment is either effective 
or not effective.  
A grade of preponderance of evidence indicates that the majority of the studies reviewed are consistent in 
their findings that treatment is either effective or not effective.  
A grade of limited evidence indicates that the studies had limited generalizability to the population of 
interest and/or the studies had a fatal flaw in research design or implementation. 
A grade of inconclusive evidence indicates that although some studies included in the medical 
effectiveness review find that a treatment is effective, a similar number of studies of equal quality suggest 
the treatment is not effective. 
A grade of insufficient evidence indicates that there is not enough evidence available to know whether or 
not a treatment is effective, either because there are too few studies of the treatment or because the 
available studies are not of high quality. It does not indicate that a treatment is not effective. 
Search Terms (* indicates truncation of word stem) 
The following Medical Subject Headings (MeSH) were used to search PubMed and Cochrane:  
 
 Age Factors 
 Antineoplastic Agents/adverse effects 
 Autism Spectrum Disorder 
 Autistic Disorder 
 Birth Rate 
 Cardiovascular Diseases 
 Cerebral Palsy 
 Cleft Palate 
 Cost Benefit Analysis 
 Cost of Illness 
 Cost Savings 
 Counseling 
 Cryopreservation 
 Depression 
 Depressive Disorder 
 Developmental Disabilities 
 Down Syndrome 
 Educational Status 
 Ethnic Groups 
 Embryo Transfer 
 Fallopian Tube diseases 
 Fertility Preservation 
 Fertilization in Vitro 
 Freezing 
 Gender Identity 
 Gynecologic Surgical Procedures 
 Health Care Costs 
 Health Impact Assessment 
 Health Services Accessibility 
 Health Services Needs and Demand 
 Health Status Disparities 
 Healthcare Disparities 
 Homosexuality, Female 
 Homosexuality, Male 
 Iatrogenic Disease 
 Incidence 
 Infant, Low Birth Weight 
 Infertility/Therapy 
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 Insemination, Artificial 
 Insurance, Health  
 Insurance Coverage 
 Live Birth 
 Menopause premature 
 Minority Health 
 Neoplasms 
 Neoplasms/therapy 
 Oocytes 
 Organ Sparing Treatments 
 Outcome Assessment (Health Care) 
 Ovary/surgery 
 Pregnancy Complications 
 Pregnancy Outcome 
 Pregnancy Rate 
 Premature Birth 
 Prevalence 
 Quality of Life 
 Race Factors 
 Radiation Injuries 
 Radiotherapy/adverse effects 
 Referral and Consultation 
 Reproductive Medicine/Legislation and 
jurisprudence 
 Reproductive Techniques 
 Reproductive Techniques, Assisted 
 Risk Assessment 
 Risk Factors 
 Semen 
 Sexuality 
 Social Determinants of Health 
 Sperm Injections, 
Intracytoplasmic/adverse effects 
 Stress, Psychological 
 Surrogate Mothers 
 Tissue Banks 
 Trachelectomy 
 Transgendered Persons 
 Treatment Outcome 
 
The following keywords were used to search PubMed, Cochrane, Web of Science, EMBASE, Business 
Source Complete, and web sites: 
 
 Access 
 Adverse effect* 
 Age 
 Anxiet* 
 Artificial insemination 
 Assisted reproduction 
 Assisted reproductive technology 
 Assistive reproductive technology 
 Autism 
 Autistic 
 Barrier* 
 Behavioral disorder* 
 Birth 
 Birth outcomes 
 Birth rates 
 Cancer* 
 Cancer therapy 
 Cancer treatment* 
 Cardiovascular disease* 
 Cerebral palsy 
 Childhood tumors 
 Cleft palate 
 Complications 
 Conservative gynecologic surgery 
 Consultation* 
 Cost* 
 Cost offset 
 Cost savings 
 Cost effective* 
 Cost utility 
 Counsel* 
 Cryopreservation 
 Death 
 Depression 
 Demand 
 Demographic* 
 Developmental disabilit* 
 Discrimination* 
 Disparit* 
 Down’s syndrome 
 Economic loss 
 Education  
 Educational attainment 
 Educational status 
 Effects of insurance mandates 
 Effective* 
 Embryo* 
 Embryo transfer 
 Ethnic* 
 Ethnic disparities 
Analysis of California Senate Bill 600 
Current as of April 17, 2019 www.chbrp.org B-2 
 Fertilization in vitro 
 Fertility preservation 
 Financial burden 
 Freezing 
 Gonadal shielding 
 Gender 
 Harms 
 Healthy child at birth 
 Homosexual* 
 Iatrogenic infertility 
 Impact*  
 In-vitro fertilization 
 Income 
 infertility 
 Infertility insurance mandates 
 Infertility therapy 
 Infertility treatments 
 Insurance coverage 
 Insurance mandates 
 Intracytoplasmic sperm injection 
 Health outcomes 
 Lesbian* 
 Live birth rates 
 Long term impacts 
 Malformations 
 Market 
 Maternal fertility status 
 Mature oocyte cryopreservation 
 Mental retardation 
 Miscarriage 
 Morbidity 
 Mortality 
 Multiple birth rates 
 Neoplasms 
 Obstetric outcome* 
 Oocytes 
 Oophoropexy 
 Out of pocket  
 Outcome* 
 Ovarian shielding 
 Ovarian suppression 
 Ovarian tissue cryopreservation 
 Ovarian transposition 
 Perinatal outcome* 
 Physician referral 
 Postnatal growth 
 Pregnancy 
 Pregnancy completed 
 Pregnancy complication* 
 Pregnancy outcome* 
 Pregnancy rate* 
 Premature death 
 Premature menopause  
 Premature ovarian failure 
 Premium* 
 Preservation 
 Preventive fertility care treatment* 
 Price elasticity 
 Productivit* 
 Psychological 
 Quality of life 
 Race 
 Racial disparities 
 Radiation injuries 
 Referral 
 Religion 
 Religious 
 Reproductive Medicine 
 Reproductive technique* 
 Risk* 
 Risk factors 
 Safety 
 Same sex couples 
 Sex differences 
 Sexual orientation 
 Side effect* 
 Sperm Banks 
 Social determinants 
 Stigma 
 Stress 
 Surrogacy 
 Surrogate 
 Testicular suppression  
 Testicular tissue cryopreservation 
 Trachelectomy 
 Transgender* 
 Treatment outcomes 
 Treatment utilization 
 Uncovered costs 
 Utilisation 
 Utilization 
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APPENDIX C  COST IMPACT ANALYSIS: DATA 
SOURCES, CAVEATS, AND ASSUMPTIONS 
The cost analysis in this report was prepared by the members of the cost team, which consists of CHBRP 
task force members and contributors from the University of California, Los Angeles, and the University of 
California, Davis, as well as the contracted actuarial firm, Milliman, Inc40  
Information on the generally used data sources and estimation methods, as well as caveats and 
assumptions generally applicable to CHBRP’s cost impacts analyses are available at CHBRP’s website.41 
This appendix describes analysis-specific data sources, estimation methods, caveats and assumptions 
used in preparing this cost impact analysis. 
Analysis-Specific Caveats and Assumptions 
• CHBRP estimated utilization of fertility preservation services, both for baseline and postmandate, 
using cancer incidence rates grouped by sex, the peer-reviewed literature, and input from content 
experts. Cancer incidence rates for reproductive age Californians were estimated using 2015 
cancer statistics data from the online Centers for Disease Control and Prevention CDC WONDER 
database. CHBRP was able to limit the CDC WONDER database to ages 10 to 44 years, which 
closely aligns with the content expert’s recommendations for reproductive age definitions for this 
analysis of 12 to 44 years for females and 12 to 49 years for males. 
• In its analysis, CHBRP included the top 10 types of cancer whose treatments pose the highest 
iatrogenic infertility risk (see the Background section). The utilization rates, both for baseline and 
postmandate, were assumed to be consistent across all types of cancer due to the very limited 
relevant data in the literature or from content expert input. Estimates of those who use fertility 
preservation services were made using very limited relevant literature and/or from content expert 
input. The body of literature on this topic is also thin.  
• CHBRP applied findings from the study by Bann et al (2015), data from the 2017 Society for 
Reproductive Technology (SART)42 and content expert input to estimate baseline utilization for 
enrollees with and without coverage.  
o In the study by Bann et al (2015), of the 812 survey respondents living in the United States 
with complete data on fertility preservation and gender, 264 reported no interest in having 
any/any more children, thus approximately 70% of the final sample of participants (550) in the 
study were interested in having a child. Among the final sample, 49% of male and 22% of 
female cancer survivors took steps to preserve fertility. CHBRP additionally assumed females 
would be twice as likely to forgo steps to pursue cryopreservation than males due to the 
higher cost of oocyte ($10,078) and embryo ($11,254) cryopreservation compared to sperm 
cryopreservation ($468). 
o In 2017 SART data, 23% of utilization of female cryopreservation was for embryos and 77% 
for mature oocytes. 
                                                     
40 CHBRP’s authorizing statute, available at http://chbrp.com/CHBRP%20authorizing%20statute_2018_FINAL.pdf, 
requires that CHBRP use a certified actuary or “other person with relevant knowledge and expertise” to determine 
financial impact.  
41 See method documents posted here, http://chbrp.com/analysis_methodology/cost_impact_analysis.php; in 
particular, see 2019 Cost Analyses: Data Sources, Caveats, and Assumptions. 
42 https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2017 
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 CHBRP estimates postmandate utilization increases to the level of those enrollees who had 
coverage at baseline plus an additional 10% increase in utilization due to increased awareness, 
increased provider and enrollee knowledge of coverage, and a corresponding greater willingness 
to discuss fertility preservation options (Vindrola-Padros et al., 2017) that might occur with the 
passage SB 600. Postmandate, no enrollees would use cryopreservation without coverage. The 
assumed proportions of enrollees using cryopreservation by coverage at baseline and 
postmandate is shown in the table here below.  
 
  
Baseline Utilization 
Post Mandate 
Utilization 
with Coverage Fertility Preservation Method 
With 
Coverage 
Without 
Coverage 
Male – sperm cryopreservation 37.7% 34.2% 41.4% 
Female – embryo cryopreservation 7.2% 3.6% 7.9% 
Female – mature oocyte cryopreservation 23.2% 11.6% 25.5% 
 
 CHBRP estimated the unit costs for cryopreservation services based on 2016 MarketScan data 
and 2016 Consolidated Health Cost Guidelines Sources Database (CHSD). Only CHSD data was 
used for pharmacy claims. The data were limited to California commercial enrollees and further 
refined to identify only enrollees with a cryopreservation procedure. Medical and surgical services 
and drugs related to cryopreservation occurring 45 days prior to the cryopreservation were 
included and services after the cryopreservation were excluded. Services related to infertility 
treatments, such as treatments of fertility problems, intrauterine insemination, implantation, and 
surrogacy were excluded.  
 Male cryopreservation case rate includes each of the following Healthcare Common Procedure 
Coding System (HCPCS) codes: Cryopreservation of sperm (89259) and sperm isolation (89261). 
The average cost of semen analysis codes 89320 and 89322 was also included in the case rate. 
 Female oocyte cryopreservation case rate includes the following HCPCS: follicle puncture for 
oocyte retrieval (58970), oocyte identification from follicular fluid (89524), and cryopreservation of 
mature oocytes (89337).  
 Female mature embryo cryopreservation case rate includes the following HCPCS: follicle 
puncture for oocyte retrieval (58970), oocyte identification from follicular fluid (89524), 
cryopreservation of embryos (89258), sperm isolation (89261), and insemination of oocytes 
(89268). 
 The content expert indicated that 95% of women would receive one cycle. The case rates above 
were doubled for the women expected to undergo two cycles and weighted at 5%.  
 In addition to the case rates listed above, medical services occurring within 45 days prior to the 
cryopreservation procedure were added to the female cryopreservation case rates. The HCPCS 
categorized into the office/home visits, office administered drugs, inpatient radiology and 
pathology/laboratory categories by Milliman’s HCG grouper were reviewed by the content expert. 
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All codes flagged as irrelevant to cryopreservation were excluded from the analysis. The 
anesthesia codes 00840 and 00940 and imaging HCPCS 74177 were included in the other 
medical services. The average cost per woman receiving cryopreservation services was added to 
the case rate. In addition to the medical services above, the average cost of pharmaceuticals per 
woman were included in the case rate. The pharmaceuticals included in the analysis are 
presented in Table 7.  
Table 7. Pharmaceuticals Included in Average Fertility Preservation Unit Costs 
 
Pharmaceuticals 
Cabergoline 
Cetrorelix acetate 
Cetrotide 
Chorionic gonadotropin 
Chorionic gonadotropin alfa  rec 
Clomiphene citrate 
Dexamethasone 
Etonogestrel 
Follistim aq 
Follitropin alfa 
Follitropin beta 
Ganirelix acetate 
Gonal F 
Gonal F RFF 
Letrozole 
Menopur 
Metformin hcl 
Metformin hydrochloride 
Norethindrone 
Norethindrone acetate 
Novarel 
Ovidrel 
Pregnyl w diluent benzyl 
Progesterone 
Progesterone  micronized 
 
Source:  CHBRP analysis of MarketScan data, 2019.  
 The average unit costs based on 2016 data were trended to the 2020 projection period using the 
CPI-Medical rate of 2% on medical services and the Milliman HCG pharmacy rate of 7.5% on the 
pharmacy component.   
 CHBRP estimates are based on allowed claims data and may underestimate the costs of 
services not covered due to carriers’ ability to negotiate discounted rates that are unavailable to 
patients and their families. 
 SB 600 does not specify requirements regarding cost sharing or coinsurance, thus CHBRP 
assumes carriers would cover cryopreservation with the same cost-sharing structure as seen at 
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baseline. Current coverage was determined using carrier surveys. Of members who currently 
have coverage, approximately 10% of large group nongrandfathered plan and 100% of individual 
Covered California plan enrollees have the same cost-sharing structure as other major medical 
services. CHBRP assumed the cost share is equal to the actuarial value with a maximum 
payment of atypical out-of-pocket maximums for the line of business. CHBRP assumed that the 
enrollee does not have any other claims accumulated to their out-of-pocket maximum. CHBRP 
assumed a 50% coinsurance without an out of pocket maximum for enrollees with a different cost 
share. This assumption is based on the infertility riders received.   
Determining Public Demand for the Proposed Mandate 
This subsection discusses public demand for the benefits SB 600 would mandate. Considering the criteria 
specified by CHBRP’s authorizing statute, CHBRP reviews public demand for benefits relevant to a 
proposed mandate in two ways. CHBRP:  
• Considers the bargaining history of organized labor; and 
• Compares the benefits provided by self-insured health plans or policies (which are not regulated 
by the DMHC or CDI and therefore not subject to state-level mandates) with the benefits that are 
provided by plans or policies that would be subject to the mandate. 
On the basis of conversations with the largest collective bargaining agents in California, CHBRP 
concluded that unions currently do not include cost-sharing arrangements for description treatment or 
service. In general, unions negotiate for broader contract provisions such as coverage for dependents, 
premiums, deductibles, and broad coinsurance levels. 
Among publicly funded self-insured health insurance policies, the preferred provider organization (PPO) 
plans offered by CalPERS currently have the largest number of enrollees. The CalPERS PPOs currently 
provide benefit coverage similar to what is available through group health insurance plans and policies 
that would be subject to the mandate.  
To further investigate public demand, CHBRP used the bill-specific coverage survey to ask carriers who 
act as third-party administrators for (non-CalPERS) self-insured group health insurance programs 
whether the relevant benefit coverage differed from what is offered in group market plans or policies that 
would be subject to the mandate. The responses indicated that there were no substantive differences.  
Second Year Impacts on Benefit Coverage, Utilization, and Cost 
In order to develop Table 8, CHBRP has considered whether continued implementation during the 
second year of the benefit coverage requirements of SB 600 would have a substantially different impact 
on utilization of either the tests, treatments or services for which coverage was directly addressed, the 
utilization of any indirectly affected utilization, or both. To generate this table, CHBRP reviewed the 
literature and consulted content experts about the possibility of varied second year impacts and applied 
what was learned to a projection of a second year of implementation.   
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Table 8. SB 600 Impacts on Benefit Coverage, Utilization, and Cost, 2021 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with health 
insurance subject to state-level 
benefit mandates (a) 24,490,000 24,490,000 0 0% 
 Total enrollees with health 
insurance subject to SB 600 16,899,000 16,899,000 0 0% 
 Percentage of enrollees with 
health insurance subject to SB 
600 69% 69% 0 0% 
 Number of enrollees with 
fertility preservation coverage 
fully compliant with SB 600 159,216 16,899,000 16,739,784 10514% 
 Percentage of enrollees with 
fertility preservation coverage 
fully compliant SB 600 0.94% 100% 99% 10514% 
Utilization and unit cost 
 Number of enrollees of child-bearing age with cancer diagnosis where treatment might result in 
iatrogenic infertility 
    Male 2,518 2,518 0 0% 
    Female 3,741 3,741 0 0% 
    Total 6,258 6,258 0 0% 
 Number of enrollees with cancer using cryopreservation covered by insurance 
    Embryo  2 225 223 11821% 
    Mature oocyte  16 725 709 4568% 
    Sperm  17 784 767 4623% 
 Number of enrollees with cancer using cryopreservation not covered by insurance 
    Embryo  101 0 -101 -100% 
    Mature oocyte  322 0 -322 -100% 
   Sperm  633 0 -633 -100% 
 Average cost per cryopreservation procedure 
    Embryo  $11,730  $11,730  0 0% 
    Mature oocyte  $10,531  $10,531  0 0% 
    Sperm  $477  $477  0 0% 
Expenditures 
Premiums by payer 
 Private employers for group 
insurance 
$90,700,422,000 $90,706,476,000 $6,054,000 
 
0.0067% 
 CalPERS HMO employer 
expenditures (c) (b) 
$3,234,903,000 $3,235,187,000 $284,000 
 
0.0088% 
 Medi-Cal Managed Care Plan 
expenditures 
$29,186,401,000 $29,186,401,000 $0 0.0000% 
 Enrollees with individually 
purchased insurance 
$13,111,153,000 $13,112,512,000 $1,359,000 
 
0.0104% 
 Enrollees with group insurance, 
CalPERS HMOs, Covered 
California, and Medi-Cal 
Managed Care (c) 
$15,255,718,000 
$15,256,649,000 
 
$931,000 
 
0.0061% 
 
Enrollee expenses 
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 For covered benefits 
(deductibles, copayments, etc.) 
$15,636,259,000 $15,639,508,000 
 
$3,249,000 
 
0.0208% 
 
 For noncovered benefits (d) (e) $4,877,000 $0 -$4,877,000 -100% 
Total expenditures 
$167,129,733,00
0 
$167,136,733,000 
 
$7,000,000 0.0042% 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in 
employer-sponsored health insurance. This group includes commercial enrollees (including those associated with Covered 
California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.43  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents.  
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that will be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations. 
 
 
 
                                                     
43 For more detail, see Estimates of Sources of Health Insurance in California, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.   
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